[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 902
1. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog; 2008 Jun;47(6):446-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
  • Alterations of the Akt/mTOR pathway have been observed in numerous types of cancer, thus this pathway represents an exciting new target for molecular therapeutics.
  • We investigated the expression of activated Akt (p-Akt) and mTOR (p-mTOR) in patients with adenocarcinoma of the cervix and the involvement of the p-Akt/p-mTOR pathway in response to combination of inhibitor agents, rapamycin and LY294002, with conventional therapy, cisplatin, in vitro.
  • Immunohistochemistry analysis of p-Akt and p-mTOR was conducted in 26 patients with adenocarcinoma of the cervix.
  • Western blot analysis was performed to determine the protein expression involved in response to chemotherapy in cervical cancer cell lines.
  • The results showed that p-Akt and p-mTOR were identified in 50% and 53.8% of adenocarcinoma of the cervix.
  • Overall, the expression of p-mTOR is a significant prognostic marker of adenocarcinoma of the cervix and a potential molecular target for the treatment of cervical cancer.
  • Inhibition of the mTOR pathway contributes to cisplatin-induced apoptosis in cervical cancer cell lines.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Protein Kinases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18058806.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


2. Furukawa N, Oi H, Yoshida S, Shigetomi H, Kanayama S, Kobayashi H: The usefulness of photodynamic eye for sentinel lymph node identification in patients with cervical cancer. Tumori; 2010 Nov-Dec;96(6):936-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of photodynamic eye for sentinel lymph node identification in patients with cervical cancer.
  • AIMS AND BACKGROUND: We studied the potential use of sentinel lymph node identification using a near-infrared fluorescence imaging technique in the treatment of cervical cancer.
  • METHODS AND STUDY DESIGN: Directly before the start of the operation, 0.2 ml of 5 mg/ml indocyanine green was prepared and injected into 4 sites in the cervix using a 26-gauge standard needle, at 3, 6, 9 and 12 o'clock positions.
  • The median maximum tumor diameter of dissected cervical tumors was 35 mm (22-65); histology was squamous cell carcinoma in 8 patients and adenocarcinoma in 2 patients.
  • [MeSH-major] Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / pathology. Coloring Agents. Female. Humans. Indocyanine Green. Lymphatic Metastasis. Middle Aged. Photochemotherapy


3. Luo CF, Hong HL, Lu YL, Wang H, Liu MQ: [Expressions of bFGF and PTEN in cervical carcinoma and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2010 Jul;32(7):533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of bFGF and PTEN in cervical carcinoma and their clinical significance].
  • OBJECTIVE: To investigate the expressions of bFGF and PTEN in cervical carcinoma and their clinical significance.
  • METHODS: Tissue microarray technique and immunohistochemistry SP method were used to detect the expressions of bFGF and PTEN in 143 cases of invasive carcinoma of cervix (ICC) and 20 cases of normal cervical epithelium remote from tumor (NCE).
  • The relationship between the expressions of bFGF and PTEN in ICC and some factors relating to clinical pathology of cervical carcinoma such as histopathological grading, lymph node metastasis, stroma involvement and FIGO staging were analyzed.
  • CONCLUSION: The overexpression of bFGF and underexpression of PTEN are closely related to the invasion and growth of cervical carcinoma.
  • Detection of the expression of both bFGF and PTEN may be of value in further understanding the biological behavior and predicting the prognosis of cervical carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Fibroblast Growth Factor 2 / metabolism. PTEN Phosphohydrolase / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cervix Uteri / cytology. Cervix Uteri / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029699.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 103107-01-3 / Fibroblast Growth Factor 2; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


Advertisement
4. Lee WA: Gastric extremely well differentiated adenocarcinoma of gastric phenotype: as a gastric counterpart of adenoma malignum of the uterine cervix. World J Surg Oncol; 2005 May 23;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric extremely well differentiated adenocarcinoma of gastric phenotype: as a gastric counterpart of adenoma malignum of the uterine cervix.
  • BACKGROUND: Most of gastric adenocarcinoma can be simply diagnosed by microscopic examination of biopsy specimen.
  • CONCLUSION: The clinicopathologic profiles of gastric extremely well differentiated adenocarcinoma of gastric phenotype include cardiac location, fungating gross type, very similar histology to foveolar epithelial hyperplasia, foveolar mucin phenotype, lack of p53 overexpressoin and high proliferative index.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1031-5 [11014567.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Pathol Int. 2004 May;54(5):311-21 [15086835.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):854-60 [15533229.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):683-92 [12428787.001]
  • (PMID = 15907218.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1180859
  •  go-up   go-down


5. Shekari M, Sobti RC, Kordi Tamandani DM, Suri V: Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population. Arch Gynecol Obstet; 2008 Dec;278(6):517-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of methylenetetrahydrofolate reductase (MTHFR) codon (677) and methionine synthase (MS) codon (2756) on risk of cervical carcinogenesis in North Indian population.
  • Cervical cancer continues to be the most common cause of death among women in developing countries.
  • In this work, we have conducted a case-control study to assess the role of these two polymorphisms in cervical cancer development.
  • We obtained blood samples from 200 women with cervical cancer and from equal matched controls and analysed using PCR-RFLP method.
  • We found that the methylenetetrahydrofolate reductase variant CT and CT+TT genotypes decreased cervix cancer risk, statistically significant (OR:0.30, 95% CI: 0.18-0.51, P<0.001 for CT and OR:0.29, 95% CI: 0.18-0.49, P=0.0000006 for CT+TT).
  • Similarly in those patients who used oral contraceptive with variant CT genotype, there was statistically highly significant reduced risk of cervix cancer (OR:0.25, 95% CI: -0.12-0.49, P<0.001) of methylenetetrahydrofolate reductase gene.
  • For the methionine synthase, 2756 variant AG and AG+GG genotypes were similarly associated with highly significant reduced risk of cervix cancer (OR: 0.13, 95% CI: 0.07-0.26, P<0.001 for AG, and OR: 0.15, 95% CI: 0.08-0.27, P<0.001 for AG+GG) genotypes.
  • In conclusion, our study suggested that methylenetetrahydrofolate reductase and methionine synthase polymorphisms might have protective effect on the risk of cervical cancer in the North Indian women.
  • [MeSH-major] 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase / genetics. Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18351371.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.13 / 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
  •  go-up   go-down


6. Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR: Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer; 2006 May-Jun;16(3):1025-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.
  • Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical adenocarcinoma (and its precursors) in Scottish patients.
  • We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in situ, and 16 cases of normal glandular epithelium.
  • Our findings support that HPV-16, along with HPV-18, are likely to play a significant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for the reduction of adenocarcinoma and associated glandular precursors.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / etiology. Cervical Intraepithelial Neoplasia / virology. DNA Probes, HPV. Female. Genotype. Humans. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / virology. Polymerase Chain Reaction / methods. Polymorphism, Restriction Fragment Length. Prevalence. Scotland / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803480.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


7. Hwang JH, Lee JK, Lee NW, Lee KW: Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies. J Reprod Med; 2010 Jan-Feb;55(1-2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors may also occur in the female genital tract, where it occurs most commonly in the cervix.
  • We report a case of an endometrial tumor that was a combination of an SCC and endometrioid adenocarcinoma with squamous components and that penetrated half of the thickness of the uterine wall.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337215.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Synaptophysin
  •  go-up   go-down


8. Narayan K, Fisher R, Bernshaw D: Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):623-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy.
  • The purpose of this study was to show that in advanced cervical cancer patients treated with curative intent, tumor volume and uterine involvement have independent prognostic value.
  • Eligible patients were those seen at the Peter MacCallum Cancer Centre between December 1995 and June 2001, newly diagnosed with a histologic diagnosis of squamous cell carcinoma or adenocarcinoma of the cervix, FIGO-staged IB-IVA, and having undergone magnetic resonance imaging (MRI) and treated with curative intent.
  • MRI was used to determine the tumor volume and whether there was invasion of tumor into the corpus uteri.
  • We conclude that in patients with advanced cervical cancer, tumor volume and corpus invasion provide important prognostic information over and above that provided by FIGO stage, clinical tumor diameter, histology, and age.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging / standards. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome


9. Madeleine MM, Anttila T, Schwartz SM, Saikku P, Leinonen M, Carter JJ, Wurscher M, Johnson LG, Galloway DA, Daling JR: Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int J Cancer; 2007 Feb 1;120(3):650-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors.
  • Human papillomavirus (HPV) is the central etiologic factor for cervical cancer, and prior studies suggested C. trachomatis may act as an HPV cofactor.
  • We examined the C. trachomatis-cervical cancer association by serotype, histology, HPV type in the tumor, and other HPV cofactors.
  • We conducted a population-based study in the Seattle-Puget Sound area of 302 women with invasive squamous cell carcinomas (SCC), 185 women with adenocarcinomas of the cervix (AC), and 318 HPV seropositive control women.

  • Genetic Alliance. consumer health - Cervical cancer.
  • Genetic Alliance. consumer health - Chlamydia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Chlamydia Infections.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):35-9 [10585579.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):423-30 [10712889.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1911-9 [10837170.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):221-7 [10861478.001]
  • [Cites] JAMA. 2001 Jan 3;285(1):47-51 [11150108.001]
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):153-61 [11246844.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1934-40 [11280749.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1368-77 [11283058.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):171-7 [11303584.001]
  • [Cites] J Infect Dis. 2002 Feb 1;185(3):324-31 [11807714.001]
  • [Cites] BMJ. 2002 Sep 14;325(7364):572 [12228133.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):681-2 [14520711.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):431-9 [15221973.001]
  • [Cites] Epidemiology. 2004 Jul;15(4):422-7 [15232402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1624-30 [15466979.001]
  • [Cites] JAMA. 1986 Apr 4;255(13):1730-4 [3081742.001]
  • [Cites] Cancer Res. 1987 Mar 15;47(6):1706-11 [3815368.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1272-8 [1328880.001]
  • [Cites] J Clin Microbiol. 1992 Nov;30(11):2911-6 [1452662.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):955-7 [7909014.001]
  • [Cites] Curr Top Microbiol Immunol. 1994;186:101-19 [8205836.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):541-8 [8827359.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):31-4 [9036866.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):233-7 [9107427.001]
  • [Cites] Clin Dermatol. 1997 Mar-Apr;15(2):249-59 [9167909.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):25-31 [9212727.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] J Infect Dis. 1998 Jun;177(6):1710-4 [9607854.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):20-5 [10406360.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):110-5 [15756673.001]
  • [Cites] Am J Epidemiol. 2005 Oct 1;162(7):668-75 [16120706.001]
  • [Cites] Med J Aust. 2005 Nov 21;183(10):548-9 [16296981.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1481-95 [16206285.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1995;64:1-378 [16755705.001]
  • (PMID = 17096345.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA094741-02; United States / NCI NIH HHS / CN / N01 CN067009; United States / NCI NIH HHS / CA / P01CA042792; United States / NCI NIH HHS / CA / CA094741-02; United States / NCI NIH HHS / CA / R03 CA094741; United States / NCI NIH HHS / CN / N01-CN-67009; United States / NCI NIH HHS / CA / P01 CA042792; United States / NCI NIH HHS / CA / R03CA94741
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Antibodies, Viral; 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS142339; NLM/ PMC4049152
  •  go-up   go-down


10. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


11. Klemm P, Tozzi R, Köhler C, Hertel H, Schneider A: Does radical trachelectomy influence uterine blood supply? Gynecol Oncol; 2005 Feb;96(2):283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does radical trachelectomy influence uterine blood supply?
  • OBJECTIVE: Radical trachelectomy in combination with pelvic and parametric lymphadenectomy is indicated in young patients with early cervical cancer and planned pregnancy.
  • We evaluated if uterine blood supply is decreased after radical trachelectomy as one of various possible causes of preterm birth.
  • METHODS: Between October 2003 and April 2004, 14 consecutive patients with early cervical cancer underwent radical trachelectomy with pelvic and parametric lymphadenectomy.
  • The uterine blood supply was measured as resistance index (RI) by Doppler sonography pre- and postoperatively.
  • Doppler sonography of the uterine artery was also performed in 14 healthy students as a control cohort.
  • RESULTS: Fourteen patients with histologically confirmed adenocarcinoma or squamous carcinoma of the cervix uteri stage Ia1 L1 to 1b1 underwent radical trachelectomy.
  • On average, 11.5 mm (5-23) of cervical length and 24.6 (14-35) tumor-free lymph nodes were removed.
  • Decrease of RI of the uterine artery was 0.06 on the right side (0.76-0.70) and 0.07 (0.75-0.68) on the left side.
  • CONCLUSION: Uterine perfusion after radical trachelectomy with pelvic and parametric lymphadenectomy remains unchanged.
  • [MeSH-major] Gynecologic Surgical Procedures / adverse effects. Uterine Cervical Neoplasms / surgery. Uterus / blood supply
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymph Node Excision / adverse effects


12. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology


13. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL: Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol; 2005 Jan;96(1):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
  • OBJECTIVES: Standard primary treatment for locally advanced cervix cancer is radiation (RT) with concomitant platinum-based chemotherapy (CT).
  • Paclitaxel and carboplatin are active agents in recurrent cervical carcinoma, have potent, synergistic in vitro radiosensitization, and are cytotoxic in weekly schedules.
  • This study was done to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly paclitaxel/carboplatin chemoradiotherapy in locally advanced cervix cancer.
  • METHODS: Women with primary, previously untreated, squamous cell or adenocarcinoma of the cervix, FIGO stage IB(2) to IVA, negative para-aortic lymph nodes, adequate organ function and performance status were eligible.
  • Fourteen patients received brachytherapy (LDR: 8, HDR: 6), and one received external RT only due to cervical stenosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy


14. Huang M, Li WC, Gao DL, Wang YP, Gu YL: [Mutation and protein expression of PTEN gene in cervical adenocarcinoma and glandular intraepithelial neoplasia]. Zhonghua Bing Li Xue Za Zhi; 2009 Jun;38(6):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation and protein expression of PTEN gene in cervical adenocarcinoma and glandular intraepithelial neoplasia].
  • OBJECTIVE: To investigate PTEN expression and mutation status in the development of cervical adenocarcinoma.
  • METHODS: Immunohistochemistry study of PTEN protein was performed on 42 cases of cervical adenocarcinoma, 20 cases of cervical glandular intraepithelial neoplasia and 28 cases of normal cervix tissue samples.
  • RESULTS: Positive expression rates of PTEN protein were 54.8% (23/42), 25.0% (5/20) and 100% (28/28) in cervical adenocarcinoma, cervical glandular intraepithelial neoplasia and normal cervix tissues, respectively.
  • Positive expression rates of PTEN protein were 47.4% (9/19), 20.0% (2/10) and 92.3% (12/13) in mucinous, endometrioid and the other variants of cervical adenocarcinoma, respectively.
  • Mutation rates at exon 5 and exon 8 of PTEN gene were 19.0% (8/42), 45.0% (9/20) and 0 in cervical adenocarcinoma, cervical glandular intraepithelial neoplasia and normal cervix tissue, respectively.
  • The mutation rates were 21.1% (4/19) and 40.0% (4/10) in mucinous and endometrioid variants of cervical adenocarcinoma, respectively.
  • There was no mutation at exons 5 and 8 of PTEN gene detected in other variants of cervical adenocarcinoma.
  • CONCLUSION: The development of cervical adenocarcionomas is correlated with the mutation and absence of the protein expression of PTEN, likely in the early phase of their carcinogenesis.
  • [MeSH-major] Adenocarcinoma / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Mutation. PTEN Phosphohydrolase. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / metabolism. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Cervix Uteri / metabolism. Exons. Female. Humans. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781347.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


15. Hebbar V, Damera G, Sachdev GP: Differential expression of MUC genes in endometrial and cervical tissues and tumors. BMC Cancer; 2005 Sep 27;5:124
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MUC genes in endometrial and cervical tissues and tumors.
  • The objective of this study was to investigate the expression of human MUC genes (MUC1, MUC2, MUC5B, MUC5AC and MUC8) in human endometrium and cervix, and to compare and quantitate the expression of MUC genes in normal and cancerous tissues.
  • RESULTS: Of the five-mucin genes studied, MUC1, MUC5B and MUC8 showed high expression levels in the normal and cancerous endometrial and cervical tissues, MUC2 and MUC5AC showed considerably lower expression.
  • Statistically, higher levels of MUC1, MUC5B and MUC8 were observed in endometrial adenocarcinomas compared to normal tissues.
  • In contrast, only MUC1 levels increased with no significant changes in expression of MUC5B and MUC8 in cervical tumors over normal cervical tissues.
  • Only MUC1 appears to be increase, in cervical tumors.
  • Low to neglible levels of MUC2 and MUC5AC were observed in all studied endometrial and cervical tissues.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1996 Mar-Apr;53(2):118-26 [8604237.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):856-61 [11093805.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 28;1406(3):251-9 [9630659.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15386-96 [11278696.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27371-5 [11369781.001]
  • [Cites] J Korean Med Sci. 2002 Feb;17(1):29-33 [11850585.001]
  • [Cites] J Pathol. 2002 Aug;197(5):632-7 [12210083.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Jpn J Clin Oncol. 2002 Dec;32(12):525-9 [12578901.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Mar;28(3):267-70 [12594051.001]
  • [Cites] Am J Reprod Immunol. 1996 Mar;35(3):261-6 [8962658.001]
  • [Cites] Fertil Steril. 1996 Aug;66(2):316-26 [8690123.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):112-21 [9036879.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Mar;16(3):232-41 [9070607.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):999-1011 [9096884.001]
  • [Cites] J Surg Oncol. 2003 Aug;83(4):253-60 [12884239.001]
  • [Cites] Hum Reprod. 1988 Oct;3(7):826-34 [3182973.001]
  • [Cites] J Biol Chem. 1989 Apr 15;264(11):6480-7 [2703501.001]
  • [Cites] Hum Reprod. 1989 Apr;4(3):236-42 [2469695.001]
  • [Cites] Biochem J. 1990 Mar 15;266(3):757-63 [1691631.001]
  • [Cites] Eur J Biochem. 1990 May 20;189(3):475-86 [2112460.001]
  • [Cites] Tumour Biol. 1990;11(5):274-86 [1697426.001]
  • [Cites] J Biol Chem. 1990 Sep 5;265(25):15286-93 [1697589.001]
  • [Cites] J Reprod Fertil. 1991 Jul;92(2):525-41 [1886107.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1992;27(1-2):57-92 [1727693.001]
  • [Cites] Am J Physiol. 1992 Oct;263(4 Pt 1):L413-29 [1415719.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Dec;7(6):557-64 [1449803.001]
  • [Cites] Fertil Steril. 1993 Dec;60(6):1011-9 [7694876.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):337-42 [8106621.001]
  • [Cites] Eur J Biochem. 1994 Sep 1;224(2):787-95 [7925397.001]
  • [Cites] Crit Rev Oncol Hematol. 1994 Dec;17(3):153-80 [7865137.001]
  • [Cites] Hum Reprod. 1995 Jan;10(1):98-102 [7745080.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2681-90 [7780985.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3639-47 [7628404.001]
  • [Cites] Biol Reprod. 1999 Jan;60(1):58-64 [9858486.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Ann Thorac Surg. 1999 Mar;67(3):810-4 [10215233.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):45-54 [10227724.001]
  • [Cites] Cancer Lett. 1999 Jul 19;142(1):121-7 [10424790.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):466-9 [10502721.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2240-5 [10521973.001]
  • [Cites] Hepatogastroenterology. 2005 Mar-Apr;52(62):398-403 [15816444.001]
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):377-88 [10681391.001]
  • [Cites] Biosci Rep. 1999 Oct;19(5):473-83 [10763814.001]
  • [Cites] Clin Biochem. 2000 Apr;33(3):167-73 [10913513.001]
  • [Cites] Tumour Biol. 1996;17(3):176-92 [8638091.001]
  • (PMID = 16188033.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL34012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC5B protein, human; 0 / MUC8 protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-5B; 0 / Mucins; 63231-63-0 / RNA
  • [Other-IDs] NLM/ PMC1249559
  •  go-up   go-down


16. Kos M, Sarkanj-Golub R, Cupić H, Balicević D: [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri]. Acta Med Croatica; 2005;59(4):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri].
  • A modification of The Bethesda System classification of cytologic findings of uterine cervix named Zagreb 1990 has been accepted in Croatia as a unique classification, the use of which has begun after the publication and printing of the new, uniform method of cytologic examination.
  • AIM: The aim of this study was to assess the number and type of cytologic abnormalities of uterine cervix classified according to Zagreb 1990, on routinely examined Pap smears during the 6-year period, and to investigate the connection of these abnormalities with lower genital tract infections.
  • A total of 59901 Pap smears (patients aged 17-79) were routinely examined: the cytopathologic diagnosis of CIN I or higher recorded in 3664 (6.12%) of them.
  • Endocervical adenocarcinoma was cytologically diagnosed in only 0.0055% of all Pap smears examined.
  • It is concluded that inflammation very likely contributes to the development of precancerous lesions of the cervix, HPV and Chlamydia showing strongest correlation, at least in a part of our population.
  • [MeSH-major] Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adolescent. Adult. Aged. Epithelium / pathology. Female. Humans. Infection / complications. Infection / diagnosis. Inflammation. Middle Aged. Uterine Cervical Diseases / complications. Uterine Cervical Diseases / microbiology


17. Manfredi R, Gui B, Giovanzana A, Marini S, Di Stefano M, Zannoni G, Scambia G, Bonomo L: Localized cervical cancer (stage &lt;IIB): accuracy of MR imaging in planning less extensive surgery. Radiol Med; 2009 Sep;114(6):960-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized cervical cancer (stage <IIB): accuracy of MR imaging in planning less extensive surgery.
  • PURPOSE: This study was undertaken to determine the accuracy of magnetic resonance (MR) imaging in the preoperative staging of patients with clinically localised cervical cancer eligible for less extensive surgery.
  • MATERIALS AND METHODS: Fifty-three patients with biopsy-proven carcinoma of the uterine cervix and eligible for conservative surgery prospectively underwent MR imaging.
  • Images were assessed for tumour site and size, infiltration of the cervical stroma, infiltration of vaginal fornices and relationship between the tumour and the internal os of the endocervical canal and the presence and dimensions of pelvic and lumboaortic lymph nodes (cutoff values 1 cm and 0.5 cm minimum axial diameter).
  • RESULTS: The endocervix was the site of origin of 25% (13/53) of the cervical tumours and the exocervix the site of origin of 75% (40/53).
  • In the assessment of cervical stroma infiltration, there was agreement between MR imaging and histopathology in 75% of cases.
  • CONCLUSIONS: MR imaging had a high level of accuracy in the preoperative assessment of the extent of cervical tumour in patients eligible for conservative surgery.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / pathology


18. Salani R, Puri I, Bristow RE: Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol; 2009 Feb;200(2):182.e1-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.
  • OBJECTIVE: We sought to determine the value of conization margin status in predicting residual and recurrent adenocarcinoma in situ (ACIS) of the cervix.
  • Invasive adenocarcinoma was more commonly associated with positive margins (5.2%) compared with negative margins (0.1%).
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Conization. Neoplasm Recurrence, Local / epidemiology. Neoplasm, Residual / epidemiology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cervix Uteri / pathology. Female. Humans. Predictive Value of Tests. Reoperation


19. Baker AC, Eltoum I, Curry RO, Stockard CR, Manne U, Grizzle WE, Chhieng D: Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. Arch Pathol Lab Med; 2006 Oct;130(10):1510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix.
  • OBJECTIVE: To determine the expression of mucins in uterine cervical glandular lesions and whether mucin expression correlates with the nature and origin of the glandular lesions.
  • DESIGN: Antibodies to MUC1, MUC2, MUC4, and MUC5AC were applied on 52 cases including 14 endocervical adenocarcinomas (including 4 adenosquamous carcinomas), 9 endometrial carcinomas (8 endometrioid adenocarcinomas and 1 adenosquamous carcinoma), 8 adenocarcinoma in situ (AIS), 2 glandular dysplasias, 6 tubal metaplasias, 10 microglandular hyperplasias, and 3 normal endocervix.
  • Almost all endocervical AIS and carcinomas and all endometrial adenocarcinomas expressed MUC1; the exceptions were 2 cases of endocervical adenocarcinoma and 1 case of adenosquamous carcinoma of the endocervix.
  • MUC2 staining was noted in 25%, 40%, and 22% of AIS, endocervical adenocarcinomas, and endometrial adenocarcinomas, respectively.
  • About 38% of AIS, 75% of endocervical adenocarcinomas, and 44% of endometrial adenocarcinomas expressed MUC4.
  • Half of AIS, most of endocervical adenocarcinomas, and 22% of endometrial adenocarcinomas expressed MUC5AC.
  • These results suggest that mucin staining may potentially be helpful in differentiating various uterine cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Mucins / metabolism. Uterine Cervical Diseases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090193.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MUC2 protein, human; 0 / MUC4 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


20. Togami S, Nomoto M, Higashi M, Goto M, Yonezawa S, Tsuji T, Batra SK, Douchi T: Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res; 2010 Jun;36(3):588-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix.
  • AIM: Only limited data are available regarding mucin antigen expression in adenocarcinoma of the uterine cervix.
  • METHODS: Fifty-two patients with mucinous adenocarcinoma of the endocervical type were enrolled for making clear implication of the mucin antigens.
  • RESULTS: The majority of mucinous adenocarcinoma showed overexpression of MUC1 and MUC16.
  • In cases classified as FIGO stage Ib (n = 35), after adjusting for patient age at diagnosis and stratifying by histological grade, MUC1 and/or MUC 16 overexpression was an independent prognostic factor for overall survival (hazard ratio [HR] = 6.16, 95% confidence interval [CI] = 1.01-118.5, P < 0.05).
  • CONCLUSION: The expressions of MUC1 and/or MUC16 may be available as independent prognostic factors for the endocervical type of mucinous adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. CA-125 Antigen / metabolism. Membrane Proteins / metabolism. Mucin-1 / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


21. Newbold RR, Jefferson WN, Padilla-Banks E: Prenatal exposure to bisphenol a at environmentally relevant doses adversely affects the murine female reproductive tract later in life. Environ Health Perspect; 2009 Jun;117(6):879-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More severe pathologies observed in some BPA-treated animals included atypical hyperplasia and stromal polyps of the uterus; sarcoma of the uterine cervix; and mammary adenocarcinoma.

  • Hazardous Substances Data Bank. BISPHENOL A DISODIUM SALT .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. BISPHENOL A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matern Child Nutr. 2005 Jul;1(3):130-41 [16881892.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):12033-8 [16882715.001]
  • [Cites] Mol Endocrinol. 2006 Sep;20(9):2141-55 [16613991.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):80-6 [17366824.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):383-90 [17123778.001]
  • [Cites] Reprod Toxicol. 2007 Apr-May;23(3):290-6 [17321108.001]
  • [Cites] Reprod Toxicol. 2007 Aug-Sep;24(2):178-98 [17628395.001]
  • [Cites] Reprod Toxicol. 2007 Aug-Sep;24(2):253-8 [17804194.001]
  • [Cites] Horm Behav. 2006 Jun;50(1):85-93 [16540110.001]
  • [Cites] Reprod Toxicol. 2007 Aug-Sep;24(2):139-77 [17825522.001]
  • [Cites] J Atheroscler Thromb. 2007 Oct;14(5):245-52 [17938543.001]
  • [Cites] Environ Health Perspect. 2008 Jan;116(1):39-44 [18197297.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):251-7 [18223485.001]
  • [Cites] Reprod Toxicol. 2008 Feb;25(2):169-76 [18295446.001]
  • [Cites] Environ Health Perspect. 1993 Oct;101(5):372-7 [8119245.001]
  • [Cites] Development. 1994 Feb;120(2):335-45 [7908629.001]
  • [Cites] Am J Pathol. 1986 Sep;124(3):405-11 [3766701.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Carcinogenesis. 1992 Feb;13(2):145-51 [1740003.001]
  • [Cites] Eur J Cancer. 1992;28A(6-7):1182-9 [1627392.001]
  • [Cites] Eur J Cancer. 1992;29A(1):149-55 [1445734.001]
  • [Cites] Environ Health Perspect. 1992 Nov;98:39-43 [1486860.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):608-12 [7556016.001]
  • [Cites] Prog Clin Biol Res. 1996;394:175-82 [8778796.001]
  • [Cites] Prog Clin Biol Res. 1996;394:425-45 [8778808.001]
  • [Cites] Environ Health Perspect. 1996 Mar;104(3):298-305 [8919768.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2056-61 [9050904.001]
  • [Cites] Biol Reprod. 1997 Dec;57(6):1338-45 [9408238.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2293-8 [9450472.001]
  • [Cites] Int J Cancer. 1998 Jan 19;75(2):290-4 [9462721.001]
  • [Cites] Dev Biol. 1998 May 15;197(2):141-54 [9630742.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):228-30 [9806537.001]
  • [Cites] J Perinatol. 2008 Apr;28(4):258-63 [18273031.001]
  • [Cites] Nature. 1999 Oct 21;401(6755):763-4 [10548101.001]
  • [Cites] Lab Anim Sci. 1999 Oct;49(5):530-6 [10551455.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):235-7 [10667565.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):151-4 [10738239.001]
  • [Cites] Environ Health Perspect. 2000 Oct;108 Suppl 5:769-73 [11035980.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]
  • [Cites] Environ Health Perspect. 2001 Jul;109(7):675-80 [11485865.001]
  • [Cites] Biol Reprod. 2001 Oct;65(4):1215-23 [11566746.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Feb 15;291(1):76-8 [11829464.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):98-102 [11896564.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110(4):427-31 [11940462.001]
  • [Cites] Reprod Toxicol. 2002 Mar-Apr;16(2):117-22 [11955942.001]
  • [Cites] Toxicol Pathol. 2002 Sep-Oct;30(5):611-6 [12371671.001]
  • [Cites] Environ Health Perspect. 2002 Nov;110(11):A703-7 [12417499.001]
  • [Cites] Evol Dev. 2003 Jan-Feb;5(1):67-75 [12492412.001]
  • [Cites] Curr Biol. 2003 Apr 1;13(7):546-53 [12676084.001]
  • [Cites] Obes Res. 2003 Apr;11(4):496-506 [12690076.001]
  • [Cites] Regul Toxicol Pharmacol. 2003 Jun;37(3):407-8; author reply 409-10 [12758220.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):635-6 [12902917.001]
  • [Cites] J Obstet Gynaecol. 2003 Sep;23(5):555-60 [12963520.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13994-9 [14610279.001]
  • [Cites] Toxicol Sci. 2003 Dec;76(2):247-9 [14677558.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):142-50 [15313586.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3988-99 [7193511.001]
  • [Cites] Obstet Gynecol Annu. 1981;10:267-78 [7024873.001]
  • [Cites] Cancer Res. 1982 May;42(5):2003-11 [7066910.001]
  • [Cites] Teratology. 1983 Jun;27(3):417-26 [6879463.001]
  • [Cites] Am J Pathol. 1984 Nov;117(2):333-5 [6437233.001]
  • [Cites] Cancer Res. 1985 Oct;45(10):5145-50 [4027990.001]
  • [Cites] Teratog Carcinog Mutagen. 1985;5(6):473-80 [2874632.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):584-94 [15548368.001]
  • [Cites] Biol Reprod. 2005 Jun;72(6):1344-51 [15689538.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2005 Jul;73(7):478-80 [15959888.001]
  • [Cites] Environ Health Perspect. 2005 Aug;113(8):969-77 [16079065.001]
  • [Cites] Environ Health Perspect. 2006 Jan;114(1):106-12 [16393666.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):110-5 [16377264.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S50-5 [16690801.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S11-7 [16690809.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5624-32 [16740699.001]
  • [CommentIn] Environ Health Perspect. 2009 Jun;117(6):A256 [19590670.001]
  • (PMID = 19590677.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Endocrine Disruptors; 0 / Phenols; 0 / Water Pollutants, Chemical; 731DCA35BT / Diethylstilbestrol; MLT3645I99 / bisphenol A
  • [Other-IDs] NLM/ PMC2702400
  • [Keywords] NOTNLM ; BPA / DES / carcinogenesis / development / diethylstilbestrol / endocrine disruptors / ovary / reproduction / toxicology / uterus
  •  go-up   go-down


22. Missaoui N, Hmissa S, Trabelsi A, Frappart L, Mokni M, Korbi S: Cervix cancer in Tunisia: clinical and pathological study. Asian Pac J Cancer Prev; 2010;11(1):235-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervix cancer in Tunisia: clinical and pathological study.
  • INTRODUCTION: Uterine cervix cancer is the second most commonly diagnosed cancer among women worldwide.
  • DESIGN: In order to review the clinical and pathological features of cervix cancer in the center of Tunisia, a retrospective study was carried out on 410 cancer cases diagnosed in the Pathology Department, Farhet Hached University Hospital, Sousse, Tunisia (1993-2006).
  • Of the 410 patients, 90.5% had squamous cell carcinoma and 7.3% had adenocarcinoma.
  • CONCLUSION: A relatively large proportion of patients presented in stages II to IV, as compared to only 36% with early stages, emphasizing the need to reinforce the early detection of this cancer and its precursor lesions in the center of Tunisia.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593963.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  •  go-up   go-down


23. Sauder K, Wilbur DC, Duska L, Tambouret RH: An approach to post-radical trachelectomy vaginal-isthmus cytology. Diagn Cytopathol; 2009 Jun;37(6):437-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radical trachelectomy (RT) is the surgical amputation of the uterine cervix with paracervical lymphadenectomy, performed in reproductive age women to treat invasive squamous-cell carcinoma or endocervical adenocarcinoma while preserving the uterine corpus for potential child bearing.
  • Fifty-four post-RT vaginal-isthmic cytology specimens were reviewed from nine patients, seven with adenocarcinoma, and two with squamous-cell carcinoma.
  • The cytology specimens most often interpreted as AGC contained many groups of hyperchromatic crowded glandular cells and/or stromal cells derived from direct sampling of the lower uterine segment.
  • In particular, a primary diagnosis of adenocarcinoma makes differentiating benign reactive glandular cells from recurrence a critical issue.
  • [MeSH-major] Cervix Uteri / surgery. Cytological Techniques / methods. Vagina / pathology

  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19217064.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Asensio N, Luis A, Costa I, Oliveira J, Vaz F: Meningeal carcinomatosis and uterine carcinoma: three different clinical settings and review of the literature. Int J Gynecol Cancer; 2009 Jan;19(1):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal carcinomatosis and uterine carcinoma: three different clinical settings and review of the literature.
  • INTRODUCTION: Leptomeningeal carcinomatosis is a rare metastatic event in gynecological neoplasias, and most cases occur in ovarian cancer.
  • It is extremely infrequent in cervical cancer, and so far, there are not any reports of this complication in association with endometrial cancer.
  • PATIENTS AND METHODS: We report a case of leptomeningeal carcinomatosis secondary to endometrial carcinoma and 2 complex cervix cancer cases.
  • A MEDLINE search was done to review all published cases of this complication in gynecological cancer to identify predictive factors for this diagnosis.
  • RESULTS AND DISCUSSION: Leptomeningeal carcinomatosis is usually diagnosed late in the course of the disease, and most reports concern ovarian cancer patients.
  • The number of cases describing this neurologic complication in cervix cancer is increasing.
  • Gadolinium-enhanced magnetic resonance imaging may be necessary for this diagnosis, because cerebrospinal fluid analysis results may be negative.
  • Most cervix cases had squamous cell (8/14) or neuroendocrine histologic subtype (3/14), and when reported, differentiation was usually poor.
  • The case we report of endometrial carcinoma, unique in the literature, is a serous adenocarcinoma.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / pathology. Meningeal Neoplasms / secondary. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology


25. Zelmanowicz Ade M, Schiffman M, Herrero R, Goldstein AM, Sherman ME, Burk RD, Gravitt P, Viscidi R, Schwartz P, Barnes W, Mortel R, Silverberg SG, Buckland J, Hildesheim A: Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: results from two studies conducted in Costa Rica and the United States. Int J Cancer; 2005 Sep 10;116(4):599-605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history as a co-factor for adenocarcinoma and squamous cell carcinoma of the uterine cervix: results from two studies conducted in Costa Rica and the United States.
  • Previous work suggests that cervical cancer may aggregate in families.
  • We evaluated the association between a family history of gynecological tumors and risk of squamous cell and adenocarcinomas of the cervix in 2 studies conducted in Costa Rica and the United States.
  • The Costa Rican study consisted of 2,073 women (85 diagnosed with CIN3 or cancer, 55 diagnosed with CIN2 and 1,933 controls) selected from a population-based study of 10,049 women.
  • The U.S. study consisted of 570 women (124 with in situ or invasive adenocarcinomas, 139 with in situ or invasive squamous cell carcinomas of the cervix and 307 community-based controls) recruited as part of a multicentric case-control study in the eastern part of the United States.
  • Information on family history of cervical and other cancers among first-degree relatives was ascertained via questionnaire.
  • Information on other risk factors for cervical cancer was obtained via questionnaire.
  • A family history of cervical cancer in a first-degree relative was associated with increased risk of squamous tumors in both studies (odds ration [OR] = 3.2 for CIN3/cancer vs. controls; 95% confidence interval [CI] = 1.1-9.4 in Costa Rica; OR = 2.6 for in situ/invasive squamous cell carcinoma cases vs. controls, 95% CI = 1.1-6.4 in the Eastern United States study).
  • No significant association was observed between a family history of cervical cancer in a first-degree relative and adenocarcinomas (OR = 1.3; 95% CI = 0.43-3.9).
  • History of gynecological tumors other than cervical cancer in a first-degree relative was not significantly associated with risk of disease in either study.
  • These results are consistent with a role of host factors in the pathogenesis of squamous cell cervical cancer, although familial aggregation due to shared environmental exposures cannot be ruled out.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / genetics. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / genetics. Genetic Predisposition to Disease. Uterine Cervical Neoplasms / etiology. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15818615.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


26. Abed Z, O'Leary M, Hand K, Flannelly G, Lenehan P, Murphy J, Foley M: Cervical screening history in patients with early stage carcinoma of the cervix. Ir Med J; 2006 May;99(5):140-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical screening history in patients with early stage carcinoma of the cervix.
  • This study aimed to examine whether a decade of heightened publicity on issues relating to cervical screening has changed the screening profile of women presenting with cervical cancer at the National Maternity Hospital.
  • The screening history of 100 women diagnosed with early/surgically treated cervical cancer between 1998 and 2002 was compared with a similar study conducted in 1982 /1990.
  • The interval between last recorded smear and diagnosis of disease was greater than 5 years in 45.6% and 41.7% respectively.
  • Overall 60% of women in the recent period had either failed to avail of screening or were not screened within 5 years of diagnosis compared with 64% in 1990.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Mass Screening / statistics & numerical data. Uterine Cervical Neoplasms / diagnosis


27. Mariño-Enríquez A, González-Rocha T, Burgos E, Stolnicu S, Mendiola M, Nogales FF, Hardisson D: Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: a clinicopathologic study of 5 cases and review of the literature. Hum Pathol; 2008 Nov;39(11):1606-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One tumor showed exclusively transitional cell differentiation, whereas the remaining 4 neoplasms showed that the transitional cell carcinoma was admixed with a variable proportions of endometrioid adenocarcinoma.
  • Four cases were in FIGO stage IB, whereas the remaining tumor infiltrated the uterine cervix (FIGO stage IIB).

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620731.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


28. Weynand B, Delvenne P, Polet R, Guiot Y, Arafa M, Somja J, Galant C: Validation of ThermoFisher's Papspin for human papillomavirus detection in cervicovaginal specimens using PCR with GP5+/GP6+ primers and the Hybrid Capture II assay. Clin Microbiol Infect; 2010 Jun;16(6):671-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty-five patients underwent conization for known lesions ranging from atypical squamous cells of undetermined significance (ASC-US) with high-risk HPV (hr-HPV) to high-grade squamous intraepithelial lesion (H-SIL/CIN2+) or adenocarcinoma.
  • Two negative controls were included: one patient with post-menopausal bleeding and another from whom an inflammatory cervical sample was taken without conization.
  • Prior to conization, a gynaecologist collected two cervical samples, fixed in PS or STM, from each patient.
  • It is concluded that ThermoFisher's PS is a valid liquid-based cytology medium for cervical samples, convenient for HPV testing by PCR with GP5+/GP6+ primers and by the HC2 assay.
  • [MeSH-major] Cervix Uteri / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Polymerase Chain Reaction / methods. Virology / methods

  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689463.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


29. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal adenocarcinomas with a pseudoendometrioid morphology, has been much publicized but albeit an appropriate supportive adjunct in many cases, exceptions from the typical staining pattern may be encountered.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


30. Singh P, Scurry J, Proietto A: Lethal endometrial recurrence after cone biopsy for microinvasive cervical adenocarcinoma. J Obstet Gynaecol Res; 2008 Jun;34(3):413-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lethal endometrial recurrence after cone biopsy for microinvasive cervical adenocarcinoma.
  • The follow up of microinvasive cervical adenocarcinoma treated conservatively is difficult because recurrences are often out of range and Pap smears difficult to interpret.
  • A 30-year-old woman with a microinvasive adenocarcinoma with clear, but narrow, margins on cone biopsy was treated conservatively.
  • After 2 years of close follow up in which no recurrence was detected, dilatation and curettage performed for infertility revealed adenocarcinoma invading secretory endometrium.
  • The carcinoma resembled her cervical adenocarcinoma histologically, immunohistochemically and was HPV DNA 16 positive.
  • A radical hysterectomy showed carcinoma involving the entire endometrium and the uppermost 3 mm of the endocervical canal, but sparing the remainder of the cervix.
  • [MeSH-major] Conization. Endometrial Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / virology. Adult. Chemotherapy, Adjuvant. DNA, Viral / analysis. Dilatation and Curettage. Fatal Outcome. Female. Human papillomavirus 16 / genetics. Humans. Hysterectomy. Immunohistochemistry. Neoplasm Invasiveness. Papanicolaou Test. Radiotherapy, Adjuvant. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588617.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


31. Klopfleisch R, van der Grinten E, Gruber AD: Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama). J Vet Diagn Invest; 2009 Mar;21(2):280-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic uterine adenocarcinoma and hepatic lipomatosis in a llama (Lama glama).
  • Postmortem examination revealed an infiltrative uterine adenocarcinoma with widespread metastases.
  • The neoplasm completely replaced and infiltrated the myometrium of the uterine body and cervix and metastasized largely to the serosal surfaces of the peritoneal cavity.
  • [MeSH-major] Adenocarcinoma / veterinary. Camelids, New World. Lipomatosis / veterinary. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary. Uterine Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19286516.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Viral Proteins
  •  go-up   go-down


32. Baek KH, Lee HJ, Kim MS, Kim YS, Seong M, Lee EJ, Lee MY: Molecular cloning of rHAUSP encoding a deubiquitinating enzyme in rat testis. Oncol Rep; 2006 Jan;15(1):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The over-expression of rHAUSP induced cell death of cervical adenocarcinoma cells.


33. Háznagy-Radnai E, Réthy B, Czigle S, Zupkó I, Wéber E, Martinek T, Falkay G, Máthé I: Cytotoxic activities of Stachys species. Fitoterapia; 2008 Dec;79(7-8):595-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activity of Stachys plants and of aucubin and harpagide against MCF7-breast adenocarcinoma, HeLa-cervix adenocarcinoma, A431-skin carcinoma of epithelial origin is reported in this study.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672034.001).
  • [ISSN] 1873-6971
  • [Journal-full-title] Fitoterapia
  • [ISO-abbreviation] Fitoterapia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cytotoxins; 0 / Glucosides; 0 / Iridoid Glucosides; 0 / Iridoid Glycosides; 0 / Iridoids; 0 / Plant Extracts; 0 / Pyrans; 2G52GS8UML / aucubin; 6926-08-5 / harpagide
  •  go-up   go-down


34. Little L, Stewart CJ: Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. Mod Pathol; 2010 Apr;23(4):611-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It may be difficult to distinguish reactive glandular lesions from adenocarcinoma in situ of the uterine cervix, and although several immunohistochemical markers have established value in this diagnostic setting, none is completely reliable.
  • Therefore, we investigated cyclin D1 staining in a series of 64 cervical biopsy specimens including examples of normal and reactive endocervical epithelium, adenocarcinoma in situ, stratified mucin-producing intraepithelial lesions, and invasive adenocarcinoma.
  • Thirteen specimens also included a component of high-grade cervical squamous intraepithelial neoplasia.
  • In contrast, most cases of adenocarcinoma in situ were completely negative and, therefore, cyclin D1 staining distinguished benign from neoplastic epithelial cells.
  • Although focal cyclin D1 expression was observed in 5/19 cases of adenocarcinoma in situ, the staining was associated with more marked cytological atypia precluding confusion with a reactive process.
  • The invasive adenocarcinomas were mainly negative for cyclin D1.
  • In conclusion, cyclin D1 can be included within an immunohistochemical panel to aid in the distinction between reactive cervical glandular lesions and adenocarcinoma in situ.
  • The localized distribution of staining within invasive lesions suggests that cyclin D1 up-regulation has a specific role during the progression of some endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin D1 / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20062011.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 136601-57-5 / Cyclin D1
  •  go-up   go-down


35. Illanes D, Broman J, Meyer B, Kredentser D, McElrath T, Timmins P 3rd: Verrucous carcinoma of the endometrium: case history, pathologic findings, brief review of literature and discussion. Gynecol Oncol; 2006 Aug;102(2):375-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A defined disease of the oral cavity, larynx, esophagus, skin, vulva, vagina and cervix.
  • But a verrucous carcinoma arising from the endometrium without evidence of cervical malignancy or endometrial adenocarcinoma is extremely rare.
  • The final histologic examination revealed a squamous cell carcinoma of endometrium, verrucous and well differentiated, and there was no cervical invasion identified.
  • CONCLUSION: This is a rare form of endometrial cancer with apparent favorable prognosis that must be considered when squamous cells are identified on endometrial samplings.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529798.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Modem RR, Otis CN, Florence RR, Pantanowitz L: Intestinal type adenocarcinoma in situ of the cervix. Diagn Cytopathol; 2007 Sep;35(9):584-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal type adenocarcinoma in situ of the cervix.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma in Situ / pathology. Intestinal Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cytological Techniques. Diagnosis, Differential. Female. Humans. Vaginal Smears


37. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lü N: [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):838-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance].
  • OBJECTIVE: To investigate and analyze the expression of fascin and CK14 in multiple histological types of cancer and to explore the potential value of the two proteins as markers in diagnosis and differential diagnosis of various cancer types.
  • METHODS: Tissue microarray containing esophageal squamous cell carcinoma (SCC), lung SCC, larynx SCC, uterine cervical SCC, SCC of external genital organs, lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, heptocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating ductal carcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, 30 cases each, as well as corresponding normal controls was constructed.
  • RESULTS: In normal esophagus, bronchus, larynx, uterine cervix and skin, fascin was mainly expressed in the basal cells or reserve cells, but the expression was diffuse in esophageal SCC, lung SCC, larynx SCC, uterine cervical SCC and SCC of external genital organs, with a positive rate of 90.0%, 90.0%, 96.7%, 78.6% and 89.7%, respectively.
  • In the normal tissue of other organs, except breast and uterine endometrium, fascin was negative.
  • In lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, the positive rates were 38.0%, 23.3%, 14.3%, 10.3%, 73.3%, 13.3%, 6.7%, 60.0%, 66.7% and 10.0%, respectively.
  • The positive rates of CK14 were 76.7%, 36.7%, 83.3%, 60.7% and 96.3% in esophageal SCC, lung SCC, larynx SCC, uterine cervical SCC and SCC of external genital organs, respectively.
  • It was weak and focal in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma, and renal clear cell carcinoma, with a positive rate of 13.3%, 13.3%, 20.7%, 41.4%, 46.7%, 6.7%, 40.0%, 13.3%, 20.0% and 6.7%, respectively.
  • Combination of fascin and CK14 should be a valuable marker in diagnosis and differential diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Keratin-14 / metabolism. Laryngeal Neoplasms / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223690.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


38. Lee EJ, Mcclelland M, Wang Y, Long F, Choi SH, Lee JH: Distinct DNA methylation profiles between adenocarcinoma and squamous cell carcinoma of human uterine cervix. Oncol Res; 2010;18(9):401-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct DNA methylation profiles between adenocarcinoma and squamous cell carcinoma of human uterine cervix.
  • The big limitation in cervical cancer research is that it is too hard to obtain the pure normal tissue from a cervical cancer mass.
  • So, we first profile type-specific DNA methylation of major two types of human uterine cervical cancer, adenocarcinoma (ACA) and squamous cell carcinoma (SCC), to establish a precise source of marker research.
  • To assess the DNA methylation status of promoter regions in human uterine cervical ACAs and SCCs, fresh frozen tissues were obtained from bulky tumor masses to minimize the contamination from normal tissues and two array platforms using digestion with methylation-sensitive restriction-enzyme HpaII, ligation, and PCR were performed: an array of 11,994 (approximately 1.5 kb) PCR products from 10,445 promoter regions, and an array of 355,264 oligonucleotides for 18,212 HpaII fragments in 12,617 promoter regions.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. DNA Methylation. Gene Expression Profiling. Uterine Cervical Neoplasms / genetics


39. Pukkala E, Malila N, Hakama M: Socioeconomic differences in incidence of cervical cancer in Finland by cell type. Acta Oncol; 2010;49(2):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic differences in incidence of cervical cancer in Finland by cell type.
  • INTRODUCTION: We studied variation in incidence of cervix cancer during 1971-1995 among Finnish women born in 1906 to 1945 by social class and cell type.
  • MATERIAL AND METHODS: The Finnish Cancer Registry data were linked to the 1970 Population Census, which included social class data.
  • There were 0.8 million individuals in the cohort under follow-up, with 5,102 squamous cell cancers and 573 cases of cervical adenocarcinoma diagnosed after the census date.
  • RESULTS: Incidence of squamous cell cancer was more than two-fold in the lowest social class (standardized incidence ratio (SIR) 1.29, 95% CI 1.21-1.36) as compared with the highest one (SIR 0.59, 0.51-0.66), while there was no association between social class and risk on adenocarcinoma (SIR 1.07, 0.87-1.28 and 1.08, 0.79-1.45, respectively).
  • DISCUSSION: Oncogenic HPV is regarded as the necessary cause of all types of cervix cancer.
  • Lack of association between adenocarcinoma and social class makes the HPV-etiology of this cell type less credible than that of squamous cell cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology


40. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C: Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol; 2006 Aug;102(2):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.
  • Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1), and 2 had endometrial cancer (1 stage IB and 1 stage IIIA).
  • Among those with cervix cancer, 12 had adenocarcinoma, 4 squamous cell carcinoma, and 2 adenosquamous carcinoma.
  • [MeSH-major] Endometrial Neoplasms / surgery. Hysterectomy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Feb;104(2):501; author reply 501-3 [17157902.001]
  • (PMID = 16472844.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


42. Parker RK, Dawsey SM, Abnet CC, White RE: Frequent occurrence of esophageal cancer in young people in western Kenya. Dis Esophagus; 2010 Feb;23(2):128-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of esophageal cancer in young people in western Kenya.
  • Esophageal cancer has a strikingly uneven geographical distribution, resulting in focal endemic areas in several countries.
  • Since 1999, the five most common cancer sites were the esophagus, stomach, prostate, colorectum, and cervix.
  • Esophageal cancer accounted for 914 (34.6%) of the 2643 newly diagnosed cancers and showed increasing trends within and outside the catchment area.
  • Fifty-eight (6.3%) patients were < or = 30 years old and 9 (1%) were < or = 20 years old; the youngest patient was 14 years at diagnosis.
  • This area of western Kenya is a high-risk region for esophageal cancer and appears unique in its large proportion of young patients.
  • Our findings support the need for further study of both environmental and genetic risk factors for esophageal cancer in this area.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2813-5 [11051353.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):240-6 [19230771.001]
  • [Cites] Cancer Detect Prev. 2006;30(1):14-9 [16495018.001]
  • [Cites] Afr Health Sci. 2005 Jun;5(2):157-63 [16006224.001]
  • [Cites] Lancet. 2005 Jun 4-10;365(9475):1971-7 [15936427.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2604-8 [2819670.001]
  • [Cites] Br J Cancer. 1969 Jun;23(2):302-12 [5788038.001]
  • [Cites] World J Gastroenterol. 2004 Jun 15;10(12):1834-5 [15188518.001]
  • [Cites] Lancet Oncol. 2003 Jul;4(7):394-6 [12850189.001]
  • [Cites] Eur J Cancer Prev. 2002 Oct;11(5):413-8 [12394237.001]
  • [Cites] Lancet. 2002 Aug 10;360(9331):462-3 [12241722.001]
  • (PMID = 19473205.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Intramural NIH HHS / / ZIA CP000185-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS416596; NLM/ PMC3505035
  •  go-up   go-down


43. Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI: Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol; 2006 Mar;107(3):701-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of atypical glandular cells on cervical cytology.
  • These data showed the following rates of pathology: 8.5% low-grade squamous intraepithelial lesions (LSIL), 11.1% high-grade squamous intraepithelial lesions (HSIL), 2.9% adenocarcinoma in situ, 1.4% endometrial hyperplasia, and 5.2% malignancy.
  • The most common malignancies were endometrial adenocarcinoma (57.6%), cervical adenocarcinoma (23.6%), ovarian and fallopian tube carcinoma (6.4%), squamous cell carcinoma of the cervix (5.4%), and other (6.9%).
  • CONCLUSION: Histologic diagnosis showed that 29.0% of these Pap tests had findings requiring follow-up or therapeutic intervention, including a 5.2% rate of malignancy.
  • Based on these findings, 99.6% of the diagnoses are within the region of surveillance when AGUS Pap tests are evaluated with colposcopy and directed biopsy, endocervical curettage, an endometrial biopsy in patients with risk factors for endometrial cancer, and pelvic examination.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Hyperplasia / pathology. Uterine Cervical Neoplasms / pathology


44. Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2009 Dec;115(3):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix.
  • OBJECTIVE: A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma.
  • METHODS: The records of 107 patients with FIGO stage IB to IIB cervical adenocarcinoma who underwent hysterectomy were reviewed.
  • Cox model analysis revealed positive cytology [hazards ratio (HR) 6.27, 95% confidence interval (CI) 2.13-18.41], positive lymph node (HR 6.20, 95% CI 1.87-20.57), ovarian metastasis (HR 5.20, 95% CI 1.18-22.82), and histological grade (HR 5.97, 95% CI 2.00-17.78) to be independent adverse risk factors for survival among the factors analyzed (lymph node status, lymph-vascular space invasion, tumor size, depth in cervical wall, pathological parametrial involvement, infiltration to vagina, ovarian metastasis, and histological grade).
  • CONCLUSION: The presence of positive peritoneal cytology appears to be an independent prognostic risk factor in patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Cavity / pathology. Uterine Cervical Neoplasms / pathology


45. Choi JS, Shin S, Jin YH, Yim H, Koo KT, Chun KH, Oh YT, Lee WH, Lee SK: Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis; 2007 Jul;12(7):1229-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have suggested that upregulation of Cyclin A-dependent protein kinase 2 (Cdk2) activity is an essential event in apoptotic progression and the mitochondrial permeability transition in human cancer cells.
  • Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252195.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / bcl-2-Associated X Protein; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


46. Bilton R, Mazure N, Trottier E, Hattab M, Déry MA, Richard DE, Pouysségur J, Brahimi-Horn MC: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem; 2005 Sep 2;280(35):31132-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we show that the ARD1 mRNA and protein levels are not regulated by hypoxia in several human tumor cell lines, including cervical adenocarcinoma HeLa cells, fibrosarcoma HT1080 cells, adenovirus-transformed human kidney HEK293 cells, and human breast cancer MCF-7 cells.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Biol Chem. 2006 Jun 2;281(22):15592
  • (PMID = 15994306.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / endothelial PAS domain-containing protein 1; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  •  go-up   go-down


47. Djordjevic B, Clement-Kruzel S, Atkinson NE, Malpica A: Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion. Am J Surg Pathol; 2010 Oct;34(10):1442-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first examined the frequency of nodal endosalpingiosis in 30 OSLMP cases, 30 cervical adenocarcinoma cases, and 30 endometrial endometrioid adenocarcinoma cases.
  • The rate of nodal endosalpingiosis was significantly higher in OSLMP cases (33%) compared with both cervical (0%, P<0.0001) and endometrial tumor cases (3%, P=0.0015).
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871218.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Martínez-Palones JM, Gil-Moreno A, Pérez-Benavente MA, Garcia-Giménez A, Xercavins J: Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis? Gynecol Oncol; 2005 Apr;97(1):292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?
  • BACKGROUND: We present a case of umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer.
  • CASE: A 59-year-old woman with stage IIIB cervical adenocarcinoma underwent laparoscopic paraaortic lymphadenectomy as well as a conventional laparoscopy to assess the presence of peritoneal carcinomatosis.
  • Seven months after completion of chemoradiotherapy, the patient presented a 2.5-cm umbilical tumor involving the trocar tract together with recurrence of the cervical mass.
  • Histological examination of the excised umbilical mass showed recurrence of the cervical adenocarcinoma, with strong peritumoral CD31 immunocytochemical expression.
  • [MeSH-major] Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Neoplasm Seeding. Umbilicus / pathology. Uterine Cervical Neoplasms / pathology


49. Sasajima Y, Mikami Y, Kaku T, Kiyokawa T, Ohishi Y, Hamada T, Sasaki T, Fujita H, Moriya T, Kasamatsu T, Tsuda H: Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix. Histopathology; 2008 Oct;53(4):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


50. Kovács A, Vasas A, Forgo P, Réthy B, Zupkó I, Hohmann J: Xanthanolides with antitumour activity from Xanthium italicum. Z Naturforsch C; 2009 May-Jun;64(5-6):343-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The isolated compounds 1-4 were evaluated for their antiproliferative activities, and were demonstrated to exert significant cell growth inhibitory activity against human cervix adenocarcinoma (HeLa), skin carcinoma (A431), and breast adenocarcinoma (MCF7) cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678536.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Plant Extracts
  •  go-up   go-down


51. Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhorst TJ: Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer; 2007 Jul 1;121(1):106-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality.
  • We investigated the significance of prognostic markers-estrogen receptor, progesterone receptor, p53, MIB-1 and bcl-2 - in adenocarcinoma of the uterine cervix.
  • In 101 patients with primary cervical adenocarcinoma, treated from 1989 to 2000, we evaluated clinical parameters in relation to these prognostic markers.
  • In conclusion, it does not seems useful to determine estrogen receptor, progesterone receptor, MIB-1 or bcl-2 in cervical adenocarcinomas as an indication of prognosis: survival is not influenced by presence or absence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / mortality


52. Kato K, Suzuka K, Osaki T, Itami M, Tanaka N: Primary hepatoid adenocarcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1150-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatoid adenocarcinoma of the uterine cervix.
  • Hepatoid adenocarcinoma is characterized histologically by neoplastic epithelial cells that resemble hepatocellular carcinoma (HCC) and produce alpha-fetoprotein (AFP).
  • We describe a case of hepatoid adenocarcinoma of the uterus that, unlike any other previously reported case, was strictly confined to the cervix.
  • A cervical biopsy demonstrated poorly differentiated adenocarcinoma, and hysterectomy and bilateral salpingo-oophorectomy were subsequently performed.
  • Histologically, the lesion consisted of solid sheets of hepatoid cells accompanied with areas of endometroid adenocarcinoma.
  • The tumor cells showed strong and diffuse cytoplasmic immunoreactivity with AFP in both medullary and adenocarcinoma components.
  • To our knowledge, this is the first report of primary hepatoid adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis


53. Yang Y, Chen L, Han BS, Xu CM, Pan HZ: [Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells]. Sheng Wu Gong Cheng Xue Bao; 2006 May;22(3):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With site-direct mutation technique, human PRNP gene was mutated and the obtained mutants were subcloned into eukaryotic expressing plasmid pcDNA3.1 and transiently expressed in Hela cervical adenocarcinoma cell.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755913.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / Mutant Proteins; 0 / Prions
  •  go-up   go-down


54. Yuan YV, Walsh NA: Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food Chem Toxicol; 2006 Jul;44(7):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary Laminaria and Porphyra sp. have been reported to reduce the risk of intestinal or mammary cancer in animal studies.
  • Thus, in the present study, we evaluated the effect of red alga, dulse (Palmaria palmata) and three kelp (Laminaria setchellii, Macrocystis integrifolia, Nereocystis leutkeana) extracts on human cervical adenocarcinoma cell line (HeLa cells) proliferation using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554116.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


55. Piketty M, Barranger E, Najat M, François P, Daraï E: Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix. Am J Obstet Gynecol; 2005 Oct;193(4):1382-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix.
  • Radical trachelectomy is an effective fertility-sparing treatment for women with early-stage cervical cancer.
  • We describe the first reported ovarian recurrence after radical trachelectomy for stage IB1 adenocarcinoma cervical cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Cervix Uteri / surgery. Neoplasms, Second Primary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery. Uterus / surgery


56. Schneider F, Mágori A, Orosz Z, Pulay T: [Atypical glandular cells (AGC) on Papanicolaou smears--the great challenge of cervix screening programs]. Orv Hetil; 2005 Oct 30;146(44):2239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypical glandular cells (AGC) on Papanicolaou smears--the great challenge of cervix screening programs].
  • PATIENTS: The aim of the study was to follow up patients with "atypical glandular cells of undetermined significance" (AGUS)/ "atypical glandular cells" (AGC), and adenocarcinoma cytological interpretation, based on a three-year material between 2000-2002 at the Department of Cytopathology of National Institute of Oncology, Hungary.
  • RESULTS: Out of 36193 conventional Papanicolaou smears, there were 276 AGC-NOS (AGUS, favour reactive in TBS1991) and 7 AGC-favour neoplastic (AGUS, favour neoplastic in TBS 1991) (altogether 0.78%) and 35 (0.1%) adenocarcinoma interpretations.
  • Histology was available in 136 (AGC-NOS: 106, AGC-favour neoplastic: 7 and adenocarcinoma: 23) cases.
  • [MeSH-major] Cervix Uteri / pathology. Mass Screening. Papanicolaou Test. Precancerous Conditions / diagnosis. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Hungary / epidemiology. Hyperplasia / diagnosis. Middle Aged. Pathology / standards


57. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ, Choy JH: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem; 2008 Nov;102(11):1991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular uptake behavior of a novel class of octahedral rhenium cluster compounds, hexahydroxo complexes K(4)[{Re(6)S(8)}(OH)(6)].8H(2)O (1) and K(4)[{Re(6)Se(8)}(OH)(6)].8H(2)O (2), was evaluated in human cervical adenocarcinoma HeLa cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783832.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Organometallic Compounds; 7440-15-5 / Rhenium
  •  go-up   go-down


58. Nam EJ, Kim SW, Kim S, Kim JH, Jung YW, Paek JH, Lee SH, Kim JW, Kim YT: A case-control study of robotic radical hysterectomy and pelvic lymphadenectomy using 3 robotic arms compared with abdominal radical hysterectomy in cervical cancer. Int J Gynecol Cancer; 2010 Oct;20(7):1284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of robotic radical hysterectomy and pelvic lymphadenectomy using 3 robotic arms compared with abdominal radical hysterectomy in cervical cancer.
  • OBJECTIVE: The purpose of this study was to compare surgical outcomes of robotic radical hysterectomy (RRH) using 3 robotic arms with those of abdominal radical hysterectomy (ARH) in the treatment of early-stage cervical cancer.
  • METHODS: Thirty-two patients with stage IA2-IIB cervical carcinoma according to the International Federation of Gynecology and Obstetrics underwent RRH between June 2006 and February 2009.
  • CONCLUSIONS: Robotic radical hysterectomy and pelvic lymphadenectomy using 3 robotic arms is feasible and preferable over ARH for the treatment of cervical cancer patients.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy. Lymph Node Excision. Pelvis / surgery. Robotics. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cervix Uteri / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Postoperative Complications. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21289494.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


59. Abhishek A, Ouseph MM, Sharma P, Kamal V, Sharma M: Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case. J Med Imaging Radiat Oncol; 2008 Feb;52(1):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case.
  • Distant cutaneous metastases from cervical malignancies are uncommon, with scalp metastases being exceptional events.
  • We present the case of a 53-year-old postmenopausal lady with adenocarcinoma of the uterine cervix that metastasized to the scalp with superior sagittal sinus thrombosis 8 months after diagnosis.
  • In contrast to the seven prior cases of scalp metastases of cervical squamous cell carcinoma reported in published reports, ours is the first documentation of such an occurrence in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Head and Neck Neoplasms / secondary. Scalp / pathology. Sinus Thrombosis, Intracranial / etiology. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cervix Uteri / radiography. Cervix Uteri / surgery. Epilepsy, Tonic-Clonic / drug therapy. Epilepsy, Tonic-Clonic / etiology. Female. Humans. Hysterectomy. Magnetic Resonance Imaging / methods. Middle Aged. Tomography, X-Ray Computed / methods


60. Amălinei C, Balan R, Stolnicu S, Rădulescu D, Boeru C, Cotuţiu C: Adenosquamous cervical carcinoma morphological characteristics. Rev Med Chir Soc Med Nat Iasi; 2005 Apr-Jun;109(2):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous cervical carcinoma morphological characteristics.
  • Adenosquamous carcinomas range between 5-25% of cervical cancers and are composed by an admixture of malignant squamous and glandular elements.
  • Differential diagnosis with endometrioid adenocarcinoma of the cervix with squamous metaplasia was made.
  • One case presented extension to the uterine body.
  • Our study concluded the occurrence of adenosquamous cervical carcinomas at a similar age with squamous cervical carcinomas in the investigated group of patients.
  • As adenosquamous cervical carcinomas are considered expressions of a biphasic differentiation of a single pluripotential sub-columnar reserve cell, a similar degree of differentiation of the two components would be expected.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies


61. Bang MH, Han MW, Song MC, Cho JG, Chung HG, Jeong TS, Lee KT, Choi MS, Kim SY, Baek NI: A cytotoxic and apoptosis-inducing sesquiterpenoid isolated from the aerial parts of Artemisia princeps PAMPANINI (Sajabalssuk). Chem Pharm Bull (Tokyo); 2008 Aug;56(8):1168-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the isolates, compound 2 exhibited potent cytotoxicity against human cervix adenocarcinoma cells and induced apoptosis.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis / genetics. Artemisia / chemistry. Cervix Uteri / pathology. Sesquiterpenes, Guaiane / isolation & purification

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670120.001).
  • [ISSN] 0009-2363
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Sesquiterpenes, Guaiane
  •  go-up   go-down


62. Ishioka S, Endo T, Hayashi T, Kitajima Y, Sugimura M, Sagae S, Saito T: Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer. Int J Clin Oncol; 2006 Apr;11(2):146-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful delivery after vaginal radical trachelectomy for invasive uterine cervical cancer.
  • A 32-year-old Japanese woman was diagnosed as having stage Ib1 adenocarcinoma by diagnostic laser conization at a local hospital.
  • The excised uterine cervix and lymph nodes were pathologically negative for cancer.
  • This is the first successful case in Japan of delivery after vaginal RT for invasive uterine cervical cancer.
  • [MeSH-major] Pregnancy Outcome. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):1002-5 [14984977.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2273-9 [10590368.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1877-82 [10760765.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):614-23 [15350349.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1491-6 [9855586.001]
  • (PMID = 16622750.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Chura JC, Brooker D, Downs LS Jr: Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature. Gynecol Oncol; 2006 Oct;103(1):336-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the urinary bladder presenting as locally advanced endometrial carcinoma. Case report and review of the literature.
  • We report a case of an adenocarcinoma arising in a defunctionalized bladder that presented as locally advanced endometrial carcinoma.
  • Examination revealed a mass protruding through the cervix and possibly involving the bladder anteriorly.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Urinary Diversion / adverse effects

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793125.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Screening has had a major impact on cervical cancer in many countries.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control


65. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1994 Apr;7(3):295-300 [7520169.001]
  • [Cites] J Pathol. 2005 Jul;206(3):305-11 [15852498.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Endocr Relat Cancer. 2005 Jun;12(2):305-17 [15947105.001]
  • [Cites] Am J Clin Pathol. 2003 Jul;120(1):71-7 [12866375.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):304-15 [18223334.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):338-42 [11301350.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1304-9 [9824112.001]
  • [Cites] Cancer. 2008 Feb 25;114(1):49-56 [18098206.001]
  • [Cites] World J Surg. 2000 Aug;24(8):913-22 [10865035.001]
  • [Cites] Lancet. 2001 May 26;357(9269):1644-50 [11425367.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1178-83 [17521698.001]
  • [Cites] Pathology. 2005 Aug;37(4):296-8 [16194828.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):242-7 [17192788.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):143-50 [11789719.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):556-64 [16814207.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):887-94 [12644826.001]
  • [Cites] Oncogene. 1997 Jun 5;14(22):2729-33 [9178771.001]
  • [Cites] Mech Dev. 1999 Oct;88(1):95-9 [10525192.001]
  • [Cites] Int J Surg Pathol. 2005 Jul;13(3):235-8 [16086077.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):696-702 [11710686.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):256-64 [16082252.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):70-4 [16614712.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):882-7 [10955455.001]
  • [Cites] Am J Clin Pathol. 2006 Nov;126(5):700-8 [17050067.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Mod Pathol. 1995 Oct;8(8):870-2 [8552578.001]
  • [Cites] Acta Cytol. 2008 Mar-Apr;52(2):133-8 [18499984.001]
  • [Cites] Virchows Arch. 1998 May;432(5):427-32 [9645441.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2676-82 [18412154.001]
  • [Cites] Histopathology. 2004 Nov;45(5):493-500 [15500653.001]
  • [Cites] Endocr Pathol. 2005 Winter;16(4):295-309 [16627917.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):188-95 [15644775.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):699-701 [12618877.001]
  • [Cites] Pathol Res Pract. 2000;196(8):533-40 [10982016.001]
  • [Cites] Endocr Pathol. 2006 Summer;17(2):109-17 [17159243.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


66. Chumworathayi B, Suprasert P, Charoenkwan K, Srisomboon J, Phongnarisorn C, Siriaree S, Cheewakriangkrai C, Tantipalakorn J, Kiatpeerakul C, Pantusart A: Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance. J Med Assoc Thai; 2005 Nov;88(11):1483-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery: a randomized comparison of treatment compliance.
  • OBJECTIVES: To compare weekly and three-weekly cisplatin as an adjunct to radiation therapy in high-risk early-stage cervical cancer after surgery with regard to treatment compliance.
  • MATERIAL AND METHOD: From June 1st, 2003 to February 29th, 2004, the authors performed a randomized trial of radiotherapy in combination with two concurrent chemotherapy regimens - weekly or three-weekly cisplatin--in patients with high-risk cervical cancer FIGO stage I-IIA after surgery.
  • Women with primary invasive squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix were enrolled.
  • CONCLUSION: Concurrent chemoradiation with weekly cisplatin regimen has more complete treatment rate and less delayed courses than that with three- weekly cisplatin among women with high-risk cervical cancer after surgery.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Patient Compliance. Uterine Cervical Neoplasms / drug therapy


67. Ratković Z, Juranić ZD, Stanojković T, Manojlović D, Vukićević RD, Radulović N, Joksović MD: Synthesis, characterization, electrochemical studies and antitumor activity of some new chalcone analogues containing ferrocenyl pyrazole moiety. Bioorg Chem; 2010 Feb;38(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The in vitro cytotoxic activity of all the synthesized compounds was studied against cervix adenocarcinoma HeLa, melanoma Fem-x and myelogenous leukemia K562 cell lines by the MTT method.

  • Hazardous Substances Data Bank. FERROCENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19846191.001).
  • [ISSN] 1090-2120
  • [Journal-full-title] Bioorganic chemistry
  • [ISO-abbreviation] Bioorg. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferrous Compounds; 0 / Pyrazoles; 5S5A2Q39HX / Chalcone; U96PKG90JQ / ferrocene
  •  go-up   go-down


68. Van Calsteren K, Hanssens M, Moerman P, Orye G, Bielen D, Vergote I, Amant F: Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy. Acta Obstet Gynecol Scand; 2008;87(2):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy.
  • Traditionally when cervical cancer is diagnosed during the first trimester of pregnancy, oncological treatment is given priority despite the pregnant state.
  • A 32-year-old primigravida was diagnosed with invasive endocervical adenocarcinoma stage Ib1 at 8 weeks' gestation.
  • As the patient wanted to preserve the pregnancy, an amputation of the anterior cervix and retroperitoneal pelvic lymphadenectomy were performed.
  • In the absence of poor prognostic markers, we decided to adopt a conservative approach for cervical adenocarcinoma in a pregnant patient at 8 weeks' gestation.
  • [MeSH-major] Adenocarcinoma / surgery. Early Diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Female. Humans. Lymph Node Excision. Pregnancy. Pregnancy Trimester, First


69. Chuang LT, Lerner DL, Liu CS, Nezhat FR: Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer.
  • A combined pelvic lymphadenectomy with radical vaginal trachelectomy is an alternative to radical hysterectomy in the treatment of young women with cervical cancer desiring fertility preservation.
  • A 30-year-old woman, gravida 1, para 1, desiring fertility preservation was given the diagnosis of invasive adenocarcinoma on cervical cone excision.
  • We hope robotic-assisted radical trachelectomy will become an option for select women with early-stage cervical cancer who desire fertility preservation.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility / physiology. Lymph Node Excision / methods. Robotics. Uterine Cervical Neoplasms / surgery


70. Lee JW, Park JA, Kim SH, Seo JH, Lim KJ, Jeong JW, Jeong CH, Chun KH, Lee SK, Kwon YG, Kim KW: Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. Cancer Sci; 2007 Sep;98(9):1476-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article protein kinase C-delta (PKC-delta) is activated by hypoxia, increases the protein stability and transcriptional activity of HIF-1alpha in human cervical adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608772.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


71. Lotan TL, Tefs K, Schuster V, Miller J, Manaligod J, Filstead A, Yamada SD, Krausz T: Inherited plasminogen deficiency presenting as ligneous vaginitis: a case report with molecular correlation and review of the literature. Hum Pathol; 2007 Oct;38(10):1569-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopically, the vagina, cervix, endometrium, ovaries, and parametrial tissues showed innumerable deposits of paucicellular hyaline material with adjacent inflammation.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Diagnosis, Differential. Female. Humans. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889676.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9001-91-6 / Plasminogen
  •  go-up   go-down


72. Han YH, Moon HJ, You BR, Park WH: The anti-apoptotic effects of caspase inhibitors on propyl gallate-treated HeLa cells in relation to reactive oxygen species and glutathione levels. Arch Toxicol; 2009 Sep;83(9):825-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we evaluated the anti-apoptotic effects of caspase inhibitors on PG-treated human cervix adenocarcinoma HeLa cells in relation to the changes of reactive oxygen species (ROS) and glutathione (GSH) levels.

  • Hazardous Substances Data Bank. PROPYL GALLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434396.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Annexin A5; 0 / Antioxidants; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Oligopeptides; 0 / Reactive Oxygen Species; 0 / benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone; 0 / benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 8D4SNN7V92 / Propyl Gallate; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; GAN16C9B8O / Glutathione
  •  go-up   go-down


73. Srilatha PS, Roy A: Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature. Indian J Pathol Microbiol; 2007 Oct;50(4):819-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature.
  • Well differentiated villoglandular adenocarcinoma of uterine cervix is a rare tumour which usually occurs in young women.
  • Physical examination revealed a cervical polyp.
  • Histopathological findings were consistent with villoglandular papillary adenocarcinoma associated with high grade cervical intraepithelial neoplasia (CIN-3).
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Adenocarcinoma, Papillary / pathology. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adnexa Uteri / pathology. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Hydronephrosis. Polyps. Ureter / pathology


74. Moreira MA, Longato-Filho A, Taromaru E, Queiroz G, Jubé LF, Pinto SA, Schmitt FC: Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesions. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):586-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of human papillomavirus by hybrid capture II in cervical carcinomas including 113 adenocarcinomas and related lesions.
  • Hybrid capture is an easy and highly sensitive technique for screening population due to its capacity to detect malignant and premalignant lesions of the cervix.
  • To evaluate its sensitivity, we investigated the frequency of high-risk human papillomavirus (HPV) infection and its correlation with glandular malignant lesions, analyzing a total of 113 cases of adenocarcinomas and related lesions.
  • The 113 glandular lesions comprised 62 invasive adenocarcinomas (IAC), 8 in situ adenocarcinomas (ISAC), 26 IAC plus SCC, and 17 adenosquamous cells carcinomas (ASCC).
  • [MeSH-major] Adenocarcinoma / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681730.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


75. McCluggage WG: Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology; 2007 Feb;39(1):97-111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemistry as a diagnostic aid in cervical pathology.
  • As with biopsies from other sites in the female genital tract, immunohistochemistry is now being increasingly used in cervical pathology as an aid to diagnosis.
  • In this review, I discuss applications of immunohistochemistry in diagnostic cervical pathology with a particular focus on recent developments.
  • Although much of this review focuses on glandular lesions, the value of markers, such as MIB1 and p16, in the assessment of pre-invasive cervical squamous lesions is discussed.
  • In the broad field of cervical glandular lesions, topics covered include: the value of markers such as MIB1, p16 and bcl-2 in distinguishing adenocarcinoma in situ and glandular dysplasia from benign mimics; markers of mesonephric lesions, including CD10; markers of value in the diagnosis of minimal deviation adenocarcinoma, such as HIK1083; markers of value in distinguishing metastatic cervical adenocarcinoma in the ovary from primary ovarian endometrioid or mucinous adenocarcinoma.
  • Rarely ectopic prostatic tissue occurs in the cervix, which can be confirmed by positive staining with prostatic markers.
  • A panel of markers, comprising oestrogen receptor, vimentin, monoclonal carcinoembryonic antigen and p16, is of value in distinguishing between a cervical adenocarcinoma and an endometrial adenocarcinoma of endometrioid type.
  • Markers of use in the diagnosis of cervical neuroendocrine neoplasms, including small cell and large cell neuroendocrine carcinoma, are discussed.
  • It is stressed that small cell neuroendocrine carcinomas may be negative with most of the commonly used neuroendocrine markers and this does not preclude the diagnosis. p63, a useful marker of squamous neoplasms within the cervix, is of value in distinguishing small cell neuroendocrine carcinoma (p63 negative) from small cell squamous carcinoma (p63 positive) and in confirming that a poorly differentiated carcinoma is squamous in type.
  • [MeSH-major] Biomarkers, Tumor / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17365826.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 104
  •  go-up   go-down


76. Jung YW, Kim SW, Kim S, Kim JH, Cho NH, Kim JW, Kim YT: Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
  • OBJECTIVE: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy.
  • STUDY DESIGN: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study.
  • COX-2 expression was associated with poor response to treatment and cancer-related death (P=0.043 and 0.012, respectively).
  • CONCLUSION: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma.
  • However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclooxygenase 1 / biosynthesis. Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836124.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


77. Numnum TM, Makhija S, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB, Curiel DT: Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol; 2008 Jan;108(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hec1 (Highly Expressed in Cancer gene 1) has recently been shown to play an important role in the proper segregation of chromosomes during mitosis.
  • Recently, an adenovirus delivery system carrying RNA interference (RNAi) of Hec1 has been reported in a cervical adenocarcinoma model.
  • METHODS: Two adenoviruses (Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3), along with a negative control (Ad-siRNA-GAPDH.F5/3), were created using homologous recombination.
  • RESULTS: QPCR demonstrated a 2-log viral infectivity enhancement with Ad-siRNA-Hec1.F5/3 over Ad-siRNA-Hec1.
  • QPCR at 72 h revealed mRNA knockdown induced by Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cells, respectively (71%/60%, and 32%/78% mRNA knockdown compared to negative control).
  • Western blot revealed translational inhibition induced by both Hec1 Ads with the least knockdown seen with Ad-siRNA-GAPDH.F5/3.
  • MTS assay indicated increased cell death 8 days post-infection with Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cell lines, respectively (75% vs. 35% and 43% vs. 12% viable cells).
  • Crystal violet staining revealed increased cell death with Ad-siRNA-Hec1.F5/3 in all tested cell lines.
  • The infectivity-enhanced adenovirus as delivery mechanism shows potential application in future gene therapy models of RNAi in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2003 Sep;8(3):449-58 [12946318.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4339-45 [14625284.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):162-71 [15233951.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):833-8 [15252144.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):785-95 [15350374.001]
  • [Cites] J Virol. 1968 May;2(5):430-9 [4301313.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2088-95 [12727824.001]
  • [Cites] Curr Biol. 2003 Jan 8;13(1):41-6 [12526743.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2267-70 [12351790.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):28-35 [11162308.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 [7638184.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3191-7 [10617568.001]
  • [Cites] Gene Ther. 1997 Sep;4(9):961-8 [9349433.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):367-72 [10419055.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):341-8 [15661219.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):519-31 [15548592.001]
  • [Cites] Gene Ther. 2006 Jan;13(1):1-7 [16121206.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36 [16361572.001]
  • [Cites] Mol Biol Rep. 2006 Mar;33(1):43-9 [16636916.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1300-10 [16622456.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):595-603 [16865275.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1319-29 [17016667.001]
  • [Cites] Curr Oncol Rep. 2006 Nov;8(6):441-7 [17040622.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1917-26 [12204675.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):275-80 [11801569.001]
  • (PMID = 18061250.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA083821-08; United States / NCI NIH HHS / CA / R01 CA083821; United States / NCI NIH HHS / CA / R01 CA083821-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDC80 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ NIHMS38788; NLM/ PMC2744403
  •  go-up   go-down


78. International Collaboration of Epidemiological Studies of Cervical Cancer: Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer; 2007 Feb 15;120(4):885-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies.
  • Squamous cell carcinomas account for about 80% of cancers of the uterine cervix, and the majority of the remainder are adenocarcinomas.
  • The International Collaboration of Epidemiological Studies of Cervical Cancer has brought together and combined individual data on 8,097 women with invasive squamous cell carcinoma, 1,374 women with invasive adenocarcinoma and 26,445 women without cervical cancer (controls) from 12 epidemiological studies.
  • Compared to controls, the relative risk of each histological type of invasive cervical cancer was increased with increasing number of sexual partners, younger age at first intercourse, increasing parity, younger age at first full-term pregnancy and increasing duration of oral contraceptive use.
  • Current smoking was associated with a significantly increased risk of squamous cell carcinoma (RR = 1.50, 95% CI: 1.35-1.66) but not of adenocarcinoma (RR = 0.86 (0.70-1.05)), and the difference between the two histological types was statistically significant (case-case comparison p < 0.001).
  • A history of screening (assessed as having had at least one previous nondiagnostic cervical smear) was associated with a reduced risk of both histological types, but the reduction was significantly greater for squamous cell carcinoma than for adenocarcinoma (RR = 0.46 (0.42-0.50) and 0.68 (0.56-0.82), respectively; case-case comparison, p = 0.002).
  • A positive test for cervical high-risk HPV-DNA was a strong risk factor for each histological type, with 74% of squamous cell carcinomas and 78% of adenocarcinomas testing positive for HPV types 16 or 18.
  • Squamous cell and adenocarcinoma of the cervix share most risk factors, with the exception of smoking.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology


79. Rischin D, Narayan K, Oza AM, Mileshkin L, Bernshaw D, Choi J, Hicks R, McClure B, Fyles A: Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer. Int J Gynecol Cancer; 2010 Jul;20(5):827-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer.
  • INTRODUCTION: Hypoxia is an adverse prognostic factor in locoregionally advanced cervical cancer treated with radiation.
  • METHODS: Eligible patients had previously untreated carcinoma of the cervix, stages IB2 to IVA.
  • Ten patients had squamous cell carcinoma and 1 patient had adenocarcinoma; 5 patients had stage 1B2 disease, 1 had stage IIA, 3 had stage IIB-3, 1 had stage IIIB, and 1 had stage IVA.
  • CONCLUSIONS: The combination of weekly tirapazamine and cisplatin with radiation for locally advanced cervical cancer was associated with more toxicity than anticipated with the recommended dose level being tirapazamine 260 mg/m and cisplatin 30 mg/m.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms, Squamous Cell / therapy. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20606530.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-62203
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triazines; 1UD32YR59G / tirapazamine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


80. Hussain SK, Sundquist J, Hemminki K: Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer; 2008 Apr 15;122(8):1873-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database.
  • Familial aggregation of cervical cancer has been demonstrated previously, however aggregation of other human papillomavirus-associated anogenital, upper aerodigestive tract and skin cancers has not been fully characterized.
  • The Swedish Family-Cancer Database, which contains reliable data on cancer incidence and nuclear family linkages for all residents of Sweden between 1958 and 2004, was used to calculate standardized incidence ratios (SIR) and 95% confidence intervals for offspring site-specific cancer risks according to site-specific cancer in sibling and parental probands.
  • Offspring cancer risk was significantly increased when either a sibling or parent was affected at the same site for penile squamous cell carcinoma (SCC, SIR = 7.54), cervical adenocarcinoma (AC, SIR = 2.31), vulvar SCC (SIR = 2.27), skin SCC (SIR = 2.14), rectal AC (SIR = 1.86), in situ cervical SCC (SIR = 1.80), invasive cervical SCC (SIR = 1.77) and upper aerodigestive tract SCC (SIR = 1.57).
  • In situ cervical SCC risk in offspring was strongly influenced by siblings affected with oropharyngeal SCC (SIR = 3.17) and tonsillar SCC (SIR = 1.84).
  • Familial skin SCC was largely unassociated with anogenital or upper aerodigestive tract cancer risk in offspring.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cluster Analysis. Family. Female. Humans. Incidence. Male. Medical Record Linkage. Middle Aged. Mouth Neoplasms / epidemiology. Odds Ratio. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Pharyngeal Neoplasms / epidemiology. Registries. Sweden / epidemiology. Tonsillar Neoplasms / epidemiology. Tumor Virus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074353.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO, Gynecologic Oncology Group: Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol; 2008 Jul;110(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
  • OBJECTIVE: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity.
  • Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen.
  • CONCLUSION: Pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cervical cancer that has failed prior chemotherapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Dexamethasone / therapeutic use. Disease Progression. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Middle Aged. Neoplasm Recurrence, Local. Patient Selection. Pemetrexed. Treatment Outcome


82. Yasuda S, Kojima A, Maeno Y, Oki N, Miyahara Y, Sudo T, Takekida S, Yamaguchi S, Nishimura R: Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis. Kobe J Med Sci; 2006;52(1-2):9-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lymphnode metastasis.
  • From January 1990 to December 2004, the prognosis of 28 patients with stage Ib1 adenosquamous cell carcinoma (ASC) were assessed in comparison with those of matched counterparts of pure adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Lymphatic Metastasis / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Staging. Pelvis. Prognosis. Retrospective Studies. Survival Rate


83. Stewart CJ, Little L: Vimentin expression in the cervix. Int J Gynecol Pathol; 2010 Jul;29(4):402-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vimentin expression in the cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Endometrial Neoplasms / pathology. Uterine Cervical Neoplasms / pathology. Vimentin / metabolism


84. Turan T, Kalantari M, Calleja-Macias IE, Cubie HA, Cuschieri K, Villa LL, Skomedal H, Barrera-Saldaña HA, Bernard HU: Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression? Virology; 2006 May 25;349(1):175-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a study designed to assess the methylation status of the HPV-18 genome, specifically of the late L1 gene, the adjacent long control region (LCR), and part of the E6 oncogene in cervical specimens with a range of pathological diagnoses.
  • In contrast, L1 sequences were strongly methylated in all cervical carcinomas, while the LCR and E6 remained unmethylated.
  • HeLa cells, derived from a cervical adenocarcinoma, contain chromosomally integrated HPV-18 genomes.
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cervix Uteri / virology. DNA Modification Methylases / antagonists & inhibitors. DNA-Binding Proteins / genetics. Enzyme Inhibitors / pharmacology. Female. HeLa Cells / virology. Humans. Oncogene Proteins, Viral / genetics. Proviruses / chemistry. Regulatory Elements, Transcriptional. Uterine Cervical Neoplasms / virology. Viral Proteins

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472835.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-91964
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Capsid Proteins; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / E6 protein, Human papillomavirus type 18; 0 / Enzyme Inhibitors; 0 / L1 protein, Human papillomavirus type 18; 0 / Oncogene Proteins, Viral; 0 / Viral Proteins; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


85. Tantipalakorn C, Khunamornpong S, Lertprasertsuke N, Tongsong T: Female genital tract tumors and gastrointestinal lesions in the Peutz-Jeghers syndrome. J Med Assoc Thai; 2009 Dec;92(12):1686-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder characterized by mucocutaneous melanin deposition, and intestinal hamartomatous polyps, with an increased risk of breast, gastrointestinal, and female genital tract cancers.
  • An ovarian microscopic cystadenoma was diagnosed together with a minimal deviation mucinous adenocarcinoma (MDA) of the uterine cervix and mucinous metaplasia in tubal mucosa and endometrium.
  • Pathological findings warranted a search for evidence of PJS Typical pigmentation at the hard palate and colonoscopic finding of hamartomatous polyps established the diagnosis of PJS.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Tract / pathology. Genital Neoplasms, Female / pathology. Genitalia, Female / pathology. Peutz-Jeghers Syndrome / diagnosis
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Cystadenoma / pathology. Cystadenoma / surgery. Female. Humans. Hysterectomy. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Risk Factors. Salpingectomy

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043574.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


86. Nagao S, Fujiwara K, Oda T, Ishikawa H, Koike H, Tanaka H, Kohno I: Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study. Gynecol Oncol; 2005 Mar;96(3):805-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of docetaxel and carboplatin in advanced or recurrent cervix cancer. A pilot study.
  • OBJECTIVES: This is a pilot study for a future trial to assess the efficacy and safety of combination chemotherapy with docetaxel and carboplatin in advanced or recurrent uterine cervix cancer.
  • METHODS: The patients eligible for this study had histologically confirmed, advanced (stage IB2-IV) or recurrent uterine cervix cancer.
  • There were 9 squamous cell carcinomas, 6 adenocarcinomas, 1 adenosquamous cell carcinoma, and 1 small cell carcinoma.
  • All 5 adenocarcinoma patients in the neoadjuvant chemotherapy group responded including 1 pathological CR.
  • CONCLUSIONS: The combination of docetaxel and carboplatin is an effective and safe treatment for uterine cervix cancer.
  • Further evaluation particularly targeted on cervical adenocarcinoma is warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721429.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


87. Niwa Y, Hirose K, Nakanishi T, Nawa A, Kuzuya K, Tajima K, Hamajima N: Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects. Gynecol Oncol; 2005 Feb;96(2):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the NAD(P)H: quinone oxidoreductase C609T polymorphism and the risk of cervical cancer in Japanese subjects.
  • OBJECTIVE: In this study, genetic polymorphisms, NQO1 C609T, GSTM1 positive/null, and GSTT1 positive/null, were examined with reference to cervical cancer risk in a population-based incident case-control study in Japanese.
  • METHODS: The cases comprised 131 cervical cancer patients: 87 cases with squamous cell carcinoma (SCC) and 44 with adenocarcinoma (ADC) or adenosquamous carcinoma (ADSC).
  • RESULTS: The cervical cancer risk was substantially elevated with smoking for all cases, SCC cases, and ADC/ADSC cases (OR = 4.50, 95% CI = 2.48-8.17, P < 0.001; OR = 5.68, 95% CI = 2.99-10.78, P < 0.001; and OR = 2.57, 95% CI = 1.09-6.08, P = 0.032; respectively).
  • Analysis of polymorphisms for GSTM1 and GSTT1 showed no significant differences between cervical cancer patients and controls.
  • CONCLUSION: This is the first report that the NQO1 gene might be important in relation to the risk of squamous cell carcinoma of the cervix.
  • [MeSH-major] NAD(P)H Dehydrogenase (Quinone) / genetics. Uterine Cervical Neoplasms / enzymology. Uterine Cervical Neoplasms / genetics

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661231.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


88. Jeong DH, Youm MY, Kim YN, Lee KB, Sung MS, Yoon HK, Kim KT: Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. Int J Gynecol Cancer; 2006 May-Jun;16(3):1234-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics.
  • This study was conducted to investigate the promoter methylation status of the p16, DAPK, CDH1, and TIMP-3 genes in primary cervical cancer and its correlation with clinicopathologic characteristics.
  • Promoter methylation was evaluated using a methylation-specific polymerase chain reaction in 78 cervical cancer tissue specimens and 24 control, normal cervical tissue specimens.
  • The frequencies of promoter methylation of p16, DAPK, CDH1, and TIMP-3 in cervical cancer were 57%, 44.9%, 52.6%, and 9%, respectively.
  • Primary cervical cancer had significantly higher methylation frequencies for the p16 and DAPK promoters than did the control, normal cervix (P < 0.0001).
  • The promoter methylation of TIMP-3 was significantly higher in adenocarcinoma than in squamous cell carcinoma (41.7% vs 3%, respectively, P= 0.0175).
  • The promoter methylation of the p16 gene is a frequent event in cervical carcinogenesis and may have potential clinical application as a marker for the progression and prognosis of cancer.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Calcium-Calmodulin-Dependent Protein Kinases / metabolism. Carcinoma / genetics. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA Methylation. Promoter Regions, Genetic. Tissue Inhibitor of Metalloproteinase-3 / metabolism. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adult. Age Factors. Aged. Cervix Uteri / metabolism. DNA, Neoplasm / metabolism. Death-Associated Protein Kinases. Female. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Lymphatic Metastasis. Middle Aged

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803511.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / Tissue Inhibitor of Metalloproteinase-3; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


89. Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ: Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer; 2006 Jan 16;94(1):171-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.
  • We present the type-distribution of high-risk human papillomavirus (HPV) types in women with normal cytology (n=1467), adenocarcinoma in situ (ACIS) (n=61), adenocarcinoma (n=70), and squamous cell carcinoma (SCC) (n=83).
  • Cervical adenocarcinoma and ACIS were significantly more frequently associated with HPV18 (OR(MH) 15.0; 95% CI 8.6-26.1 and 21.8; 95% CI 11.9-39.8, respectively) than normal cytology.
  • Human papillomavirus16 was only associated with adenocarcinoma and ACIS after exclusion of HPV18-positive cases (OR(MH) 6.6; 95% CI 2.8-16.0 and 9.4; 95% CI 2.8-31.2, respectively).
  • These results suggest that HPV18 is mainly a risk factor for the development of adenocarcinoma whereas HPV16 is associated with both SCC and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / etiology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2244-6 [11072213.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):177-81 [15900579.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jan-Feb;11(1):39-48 [11285032.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):398-404 [11487272.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):779-87 [11880393.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Lancet. 2003 Jan 4;361(9351):40-3 [12517465.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Am J Obstet Gynecol. 2003 Mar;188(3):657-63 [12634637.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):101-5 [12838308.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7215-20 [14612516.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1871-6 [14667741.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):271-6 [15018855.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):388-93 [15047743.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):94-101 [15054873.001]
  • [Cites] Int J Epidemiol. 1995 Apr;24(2):300-7 [7635589.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):791-5 [9041439.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):268-75 [15688404.001]
  • [Cites] J Infect Dis. 2005 Jun 1;191(11):1808-16 [15871112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64 [15894666.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71 [16030304.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1906-15 [11283122.001]
  • (PMID = 16404371.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361088
  •  go-up   go-down


90. de Oliveira ER, Derchain SF, Sarian LO, Rabelo-Santos SH, Gontijo RC, Yoshida A, Andrade LA, Zeferino LC: Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. Int J Gynecol Cancer; 2006 May-Jun;16(3):1055-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities.
  • The objective of this study was to assess whether human papillomavirus (HPV) detection with hybrid capture II (HC II) can help predict the presence and the nature, glandular or squamous, of histologic cervical lesions in women referred due to atypical glandular cells (AGC) or high-grade squamous intraepithelial lesion (HSIL).
  • Referral Pap smears comprised AGC (51 cases), AGC plus HSIL (28 cases), adenocarcinoma in situ (10 cases), and HSIL (158 cases).
  • All patients were tested for high-risk HPV with HC II and had a histologic assessment of their cervix.
  • Almost 70% of AGC-HPV-negative patients did not have a pathologically proven cervical neoplasia, whereas 76% of women with AGC-HPV-positive result were diagnosed with a squamous or glandular neoplasia.
  • We conclude that in women with AGC, HPV positivity strongly correlated with the presence of glandular or squamous cervical lesion but did not help distinguishing women with squamous from those with glandular neoplasia.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Mass Screening / methods. Papillomaviridae / isolation & purification. Uterine Cervical Diseases / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / epidemiology. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / epidemiology. DNA Probes, HPV. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / virology. Neoplasms, Squamous Cell / epidemiology. Neoplasms, Squamous Cell / virology. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Precancerous Conditions / virology. Predictive Value of Tests. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Dysplasia / epidemiology. Uterine Cervical Dysplasia / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Cervix Disorders.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803485.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


91. Ali TZ, Zakowski MF, Yung RC, Burroughs FH, Ali SZ: Exfoliative sputum cytology of cancers metastatic to the lung. Diagn Cytopathol; 2005 Sep;33(3):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytological diagnoses included colonic adenocarcinoma (7 cases); non-Hodgkin's lymphoma (NHL; 5 cases); malignant melanoma (MM; 5 cases); breast carcinoma (5 cases); Hodgkin's lymphoma (HL; 3 cases); pancreatic adenocarcinoma (2 cases); prostatic adenocarcinoma (2 cases); and 1 case each of urothelial carcinoma, endometrial carcinoma, renal cell carcinoma, hepatic small-cell carcinoma, squamous-cell carcinoma (cervix), and leiomyosarcoma (LMS).
  • In non-lymphoid tumors (27 cases), isolated single malignant cells were seen in 7 (26%) cases (all cases of MM and prostatic adenocarcinoma), whereas 20 (74%) cases displayed fragments with intact tumor architecture.
  • Exfoliation of cancer cells in sputum from secondary tumors in the lung is a rare phenomenon in current-day practice, with metastatic colonic adenocarcinoma seen most commonly.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Neoplasm Metastasis / diagnosis. Sputum / cytology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078247.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


93. Liu B, Zhang H, Luo X, Xie Y, Hao J, Zhou Q, Duan X, Wang Y, Zhao W: High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation. J Cancer Res Clin Oncol; 2009 Jul;135(7):925-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation.
  • PURPOSE: The aim of this study is to evaluate the effect of carbon-beam irradiation on adenovirus-mediated p53 transfer in human cervix adenocarcinoma.
  • CONCLUSIONS: The subclinical-dose C-beam irradiation could significantly promote the transfer and expression of exogenous p53, extend the duration of p53 expression, and enhance the suppression of p53 on cervix adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / therapy. Carbon Radioisotopes / therapeutic use. Gene Transfer Techniques. Genes, p53. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1989 Jun 16;244(4910):1275-81 [2660259.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1993;46:1-36 [8234781.001]
  • [Cites] Oncogene. 1997 Apr 10;14(14):1735-46 [9135075.001]
  • [Cites] Oncogene. 1995 Nov 2;11(9):1899-905 [7478620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):631-40 [14751537.001]
  • [Cites] Oncogene. 1996 Jun 6;12 (11):2369-76 [8649777.001]
  • [Cites] Acta Med Okayama. 1997 Feb;51(1):19-23 [9057931.001]
  • [Cites] Cancer Gene Ther. 1999 Mar-Apr;6(2):155-62 [10195882.001]
  • [Cites] J Biochem. 2003 Aug;134(2):219-24 [12966070.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1984 Nov;46(5):555-68 [6394531.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4466-71 [12431970.001]
  • [Cites] Ann N Y Acad Sci. 1994 May;720(1):153-159 [28621859.001]
  • [Cites] Cancer Gene Ther. 2000 Sep;7(9):1215-9 [11023193.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4891-3 [8895740.001]
  • [Cites] Nature. 1992 Jun 11;357(6378):455-60 [1608446.001]
  • [Cites] Hum Gene Ther. 1997 Jun 10;8(9):1025-32 [9189760.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5493-7 [15994918.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):609-22 [10653876.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):598-605 [14628125.001]
  • [Cites] Cancer Gene Ther. 1997 Mar-Apr;4(2):129-38 [9080122.001]
  • [Cites] Obstet Gynecol Clin North Am. 1996 Dec;23(4):735-58 [8989774.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1665-71 [9816114.001]
  • [Cites] Cancer J Sci Am. 1999 Nov-Dec;5(6):362-9 [10606478.001]
  • [Cites] J Virol. 1996 Sep;70(9):6497-501 [8709289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):803-8 [11395250.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1050-5 [8640760.001]
  • [Cites] Nature. 1993 Oct 21;365(6448):691-2 [7692307.001]
  • [Cites] Am Rev Respir Dis. 1963 Sep;88:SUPPL 394-403 [14064954.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3397-406 [7936668.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2445-9 [10499617.001]
  • [Cites] J Virol. 1994 Dec;68(12):8282-7 [7966621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):607-16 [10078646.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):563-9 [15289857.001]
  • (PMID = 19085001.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


94. Vilos GA, Edris F, Abu-Rafea B, Hollett-Caines J, Ettler HC, Al-Mubarak A: Miscellaneous uterine malignant neoplasms detected during hysteroscopic surgery. J Minim Invasive Gynecol; 2009 May-Jun;16(3):318-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miscellaneous uterine malignant neoplasms detected during hysteroscopic surgery.
  • STUDY OBJECTIVES: To estimate the incidence of incidental miscellaneous uterine malignant neoplasms other than endometrioid adenocarcinoma detected during routine resectoscopic surgery in women with abnormal uterine bleeding (AUB) and to examine the effect of hysteroscopic surgery on long-term clinical outcome.
  • After diagnosis of uterine cancer, the women were counseled about the disease and management in accord with established clinical practice guidelines.
  • MEASUREMENTS AND MAIN RESULTS: Of the 3892 women, 4 had undiagnosed and 3 had suspected miscellaneous uterine malignant neoplasms including 1 endometrial stromal sarcoma, 2 carcinosarcomas, 2 atypical polypoid adenomyomas of the endometrium, 1 minimal deviation adenocarcinoma of the cervix, and 1 smooth-muscle tumor of uncertain malignant potential.
  • At 2 to 8 years of follow-up, 1 patient died accidentally after 1 year, 1 died of carcinomatosis of either coexisting breast cancer or a carcinosarcoma (postmortem examination was declined) after 1 year, and 5 were alive and well.
  • CONCLUSION: Resectoscopic surgery in women with miscellaneous uterine malignant lesions not adversely affect 5-year survival and long-term prognosis.
  • [MeSH-major] Hysteroscopy. Metrorrhagia / surgery. Neoplasms, Complex and Mixed / diagnosis. Smooth Muscle Tumor / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423062.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


96. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T: Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett; 2008 Jun 8;264(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.
  • This study investigated associations of Cap43 expression with angiogenesis and other clinicopathological factors in cervical adenocarcinoma.
  • The clinical records of 100 women who underwent surgery for cervical adenocarcinoma were reviewed retrospectively.
  • Our results suggest that increased expression of Cap43 is associated with angiogenesis and may be a poor prognostic indicator in women with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Neovascularization, Pathologic. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281151.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


97. Liu B, Zhang H, Zhou G, Xie Y, Hao J, Zhou Q, Duan X, Qiu R: Enhanced cell death by AdCMV-p53 after irradiation of HeLa cells with 12C 6+ ions. Eur J Obstet Gynecol Reprod Biol; 2008 Jun;138(2):226-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate whether the adenovirus-mediated p53 transfer could enhance the suppression of cervix adenocarcinoma by low-dose (< or =2.0Gy) heavy-ion irradiation.
  • CONCLUSIONS: Adenovirus-mediated p53 transfer could enhance the suppression of cervix adenocarcinoma cells by low-dose C-beam irradiation.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis / radiation effects. Genes, p53. Genetic Therapy. Heavy Ions / therapeutic use. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • Hazardous Substances Data Bank. CARBON .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17904269.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 7440-44-0 / Carbon
  •  go-up   go-down


98. Chao TC, Chao HH, Jan YY, Chen MF: Perforation through small bowel malignant tumors. J Gastrointest Surg; 2005 Mar;9(3):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histopathology included lymphoma (seven patients), leiomyosarcoma (two patients), gastrointestinal stromal tumor (one patient), adenocarcinoma (one patient), metastatic carcinomas with unknown primary tumor (four patients), metastatic adenocarcinoma from the lung (one patient), and metastatic carcinomas from the hypopharynx (one patient), cervix (one patient), and lung (one patient).

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1988 Feb;6(2):291-6 [3339395.001]
  • [Cites] J Clin Gastroenterol. 2001 Oct;33(4):267-82 [11588539.001]
  • [Cites] Ann Surg. 1979 Jun;189(6):732-40 [453945.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2157-60 [9951884.001]
  • [Cites] Acta Chir Scand. 1989 Nov-Dec;155(11-12):593-9 [2618515.001]
  • [Cites] Acta Radiol. 1998 Jan;39(1):52-6 [9498870.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Surgery. 2000 Feb;127(2):178-84 [10686983.001]
  • [Cites] Ann Surg. 1996 Jul;224(1):10-8 [8678610.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Ann Surg. 1980;192(4):581-6 [7425698.001]
  • [Cites] Surgery. 1982 Oct;92(4):605-9 [6981865.001]
  • [Cites] Dis Colon Rectum. 1983 May;26(5):323-6 [6653291.001]
  • [Cites] Nihon Ika Daigaku Zasshi. 1999 Feb;66(1):37-40 [10097589.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Arch Surg. 1989 Jul;124(7):830-2 [2742484.001]
  • [Cites] Am Surg. 1989 Jul;55(7):408-12 [2787134.001]
  • [Cites] Surg Today. 2001;31(4):358-62 [11321350.001]
  • [Cites] J Am Coll Surg. 1997 Sep;185(3):250-4 [9291402.001]
  • [Cites] Am J Gastroenterol. 1999 Jul;94(7):1884-7 [10406253.001]
  • [Cites] J Surg Oncol. 1989 Aug;41(4):219-21 [2666757.001]
  • [Cites] Am J Surg. 1987 Apr;153(4):355-8 [3565679.001]
  • [Cites] Cancer. 1983 Mar 1;51(5):878-81 [6821853.001]
  • [Cites] J Clin Gastroenterol. 2000 Apr;30(3):289-93 [10777190.001]
  • [Cites] Cancer. 1978 May;41(5):1984-9 [348299.001]
  • [Cites] Ann Surg. 1981 Jan;193(1):67-9 [7458451.001]
  • (PMID = 15749607.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


99. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • Mesonephric remnants of the cervix are vestiges of the embryonic mesonephric system which typically regresses during female development.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • We demonstrated that PAX2 was strongly and diffusely expressed in mesonephric remnants (6 of 6) and in mesonephric hyperplasia (18 of 18); however, no expression was noted in mesonephric adenocarcinoma (0 of 1).
  • PAX2 was expressed in normal endocervical glands (including tunnel clusters and Nabothian cysts) (86 of 86), lobular endocervical glandular hyperplasia (5 of 5), tubal/tuboendometrioid metaplasia (8 of 8), and cervical endometriosis (13 of 14).
  • In contrast, only 2 cases of endocervical adenocarcinoma were positive for PAX2 [invasive adenocarcinoma of the minimal deviation type (0 of 5), usual type (1 of 22), and endometrioid type (1 of 1)].
  • Adjacent adenocarcinoma in situ, as well as cases of pure adenocarcinoma in situ (0 of 6), were also PAX2 negative.
  • PAX2 expression in the 2 positive endocervical adenocarcinomas was patchy and weak.
  • Most (11 of 15) stage II endometrial endometrioid adenocarcinomas lacked PAX2 expression but 1 of 10 grade 1 tumors and 3 of 5 grade 2 tumors did express PAX2.
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry / methods. Neoplasm Staging. Precancerous Conditions / diagnosis


100. Epstein E, Di Legge A, Måsbäck A, Lindqvist PG, Kannisto P, Testa AC: Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix. Ultrasound Obstet Gynecol; 2010 Oct;36(4):512-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix.
  • OBJECTIVE: The objective of this study was to describe the sonographic characteristics of squamous cell cancer (SCC) and adenocarcinoma (AC) of the cervix using transvaginal ultrasound.
  • METHODS: Women with early stage cervical cancer undergoing transvaginal ultrasound examination before surgery were prospectively included.
  • At pathological examination, 34 women had tumors confined to the cervix, three had parametrial invasion and three had vaginal invasion.
  • Color Doppler signals were found in all cases of AC and in 90% (18/20) of cases of SCC, compared with most normal cervical tissue in which virtually no detectable vascularization was found.
  • This knowledge should be useful in the clinical evaluation of cervical tumors.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Cervix Uteri / ultrasonography. Uterine Cervical Neoplasms / ultrasonography






Advertisement